Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Blood

Retrieve available abstracts of 490 articles:
HTML format
Text format



Single Articles


    May 2018
  1. LUO H, Wang F, Zha J, Li H, et al
    CTCF boundary remodels chromatin domain and drives aberrant HOX gene transcription in acute myeloid leukemia.
    Blood. 2018 May 14. pii: blood-2017-11-814319. doi: 10.1182/blood-2017-11-814319
    PubMed     Text format     Abstract available


  2. OLAIYA OO, Li W
    Frequent erythrophagocytosis by leukemic blasts in B-cell acute lymphoblastic leukemia.
    Blood. 2018;131:2178.
    PubMed     Text format    


  3. ROBINSON HR, Qi J, Cook EM, Nichols C, et al
    A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
    Blood. 2018 May 9. pii: blood-2018-02-830992. doi: 10.1182/blood-2018-02-830992.
    PubMed     Text format     Abstract available


  4. TOPP MS, Zimmerman Z, Cannell P, Dombret H, et al
    Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Blood. 2018 May 8. pii: blood-2017-09-804658. doi: 10.1182/blood-2017-09-804658.
    PubMed     Text format     Abstract available


  5. ZHU HH, Liu YR
    Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia.
    Blood. 2018 May 4. pii: blood-2018-02-834051. doi: 10.1182/blood-2018-02-834051.
    PubMed     Text format    


  6. STEIN EM, Garcia-Manero G, Rizzieri DA, Tibes R, et al
    The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
    Blood. 2018 May 3. pii: blood-2017-12-818948. doi: 10.1182/blood-2017-12-818948.
    PubMed     Text format     Abstract available


  7. HRUSAK O, De Haas V, Stancikova J, Vakrmanova B, et al
    International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia.
    Blood. 2018 May 2. pii: blood-2017-12-821363. doi: 10.1182/blood-2017-12-821363.
    PubMed     Text format     Abstract available


    April 2018
  8. LI S, Xu J
    Plasma cell leukemia presenting as "lymphocytosis".
    Blood. 2018;131:1994.
    PubMed     Text format    


  9. YANG J, LeBlanc FR, Dighe SA, Hamele CE, et al
    TRAIL mediates and sustains constitutive NF-kappaB activation in LGL leukemia.
    Blood. 2018 Apr 26. pii: blood-2017-09-808816. doi: 10.1182/blood-2017-09-808816
    PubMed     Text format     Abstract available


  10. MCKENNA MK, Noothi SK, Alhakeem SS, Oben KZ, et al
    Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
    Blood. 2018 Apr 25. pii: blood-2017-10-813931. doi: 10.1182/blood-2017-10-813931
    PubMed     Text format     Abstract available


  11. ITZYKSON R, Duployez N, Fasan A, Decool G, et al
    Clonal interference of signaling mutations holds prognostic relevance in core binding factor acute myeloid leukemia.
    Blood. 2018 Apr 24. pii: blood-2018-03-837781. doi: 10.1182/blood-2018-03-837781
    PubMed     Text format     Abstract available


  12. HASAN MK, Yu J, Widhopf GF 2nd, Rassenti LZ, et al
    Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
    Blood. 2018 Apr 20. pii: blood-2017-12-819383. doi: 10.1182/blood-2017-12-819383
    PubMed     Text format     Abstract available


  13. KLEINSTERN G, Camp NJ, Goldin LR, Vachon CM, et al
    Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.
    Blood. 2018 Apr 19. pii: blood-2017-11-814608. doi: 10.1182/blood-2017-11-814608
    PubMed     Text format     Abstract available


  14. PUENTE XS, Jares P, Campo E
    Chronic lymphocytic leukemia and mantle cell lymphoma: Crossroads of genetic and microenvironment interactions.
    Blood. 2018 Apr 17. pii: blood-2017-10-764373. doi: 10.1182/blood-2017-10-764373
    PubMed     Text format     Abstract available


  15. RANK CU, Toft N, Tuckuviene R, Grell K, et al
    Thromboembolism in Acute Lymphoblastic Leukemia: Results of NOPHO ALL2008 Protocol Treatment in Patients 1-45 Years.
    Blood. 2018 Apr 16. pii: blood-2018-01-827949. doi: 10.1182/blood-2018-01-827949
    PubMed     Text format     Abstract available


  16. WANG F, Demir S, Gehringer F, Osswald CD, et al
    Tight regulation of FOXO1 is essential for maintenance of B-cell precursor acute lymphoblastic leukemia.
    Blood. 2018 Apr 5. pii: blood-2017-10-813576. doi: 10.1182/blood-2017-10-813576.
    PubMed     Text format     Abstract available


  17. STATLER A, Othus M, Erba HP, Chauncey TR, et al
    Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies.
    Blood. 2018 Apr 4. pii: blood-2018-01-826693. doi: 10.1182/blood-2018-01-826693.
    PubMed     Text format     Abstract available


    March 2018
  18. CORTES JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, et al
    Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
    Blood. 2018 Mar 22. pii: blood-2016-09-739086. doi: 10.1182/blood-2016-09-739086
    PubMed     Text format     Abstract available


  19. RUIZ S, Chen YH
    Acute myeloid leukemia with coexistence of t(9;22) and inv(16).
    Blood. 2018;131:1263.
    PubMed     Text format    


  20. HALLEK M, Cheson BD, Catovsky D, Caligaris-Cappio F, et al
    Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia.
    Blood. 2018 Mar 14. pii: blood-2017-09-806398. doi: 10.1182/blood-2017-09-806398
    PubMed     Text format     Abstract available


  21. YAMATO G, Shiba N, Yoshida K, Hara Y, et al
    RUNX1 mutations in pediatric acute myeloid leukemia are associated with distinct genetic features and an inferior prognosis.
    Blood. 2018 Mar 14. pii: blood-2017-11-814442. doi: 10.1182/blood-2017-11-814442
    PubMed     Text format    


  22. SHOMALI W, Gotlib J
    Myelophthisic marrow involved by breast cancer and acute myeloid leukemia.
    Blood. 2018;131:1036.
    PubMed     Text format    


    February 2018
  23. KREITMAN RJ, Tallman MS, Robak T, Coutre S, et al
    Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase I results and long-term follow-up.
    Blood. 2018 Feb 27. pii: blood-2017-09-803072. doi: 10.1182/blood-2017-09-803072
    PubMed     Text format     Abstract available


  24. DUARTE D, Hawkins ED, Lo Celso C
    The interplay of leukemia cells and the bone marrow microenvironment.
    Blood. 2018 Feb 27. pii: blood-2017-12-784132. doi: 10.1182/blood-2017-12-784132
    PubMed     Text format     Abstract available


  25. LIU T, Wen L, Yuan H, Wang Y, et al
    Identification of novel recurrent CPSF6-RARG fusions in acute myeloid leukemia resembling acute promyelocytic leukemia.
    Blood. 2018 Feb 27. pii: blood-2017-11-818716. doi: 10.1182/blood-2017-11-818716
    PubMed     Text format    


  26. SCHLIFFKE S, Buhs S, Bolz S, Gerull H, et al
    The phosphotyrosine phosphatase SHP2 promotes anergy in chronic lymphocytic leukemia.
    Blood. 2018 Feb 23. pii: blood-2017-06-788166. doi: 10.1182/blood-2017-06-788166
    PubMed     Text format    


  27. JAITLY V, Wang W
    B-cell acute lymphoblastic leukemia in JAK2 V617F-positive polycythemia vera.
    Blood. 2018;131:941.
    PubMed     Text format    


  28. SIREF A, Huang Q
    Chewing the bone: bone marrow with adult T-cell leukemia/lymphoma.
    Blood. 2018;131:940.
    PubMed     Text format    


  29. GALLIPOLI P, Giotopoulos G, Tzelepis K, Costa ASH, et al
    Glutaminolysis is a metabolic dependency in FLT3(ITD) acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.
    Blood. 2018 Feb 20. pii: blood-2017-12-820035. doi: 10.1182/blood-2017-12-820035
    PubMed     Text format     Abstract available


  30. WIERZ M, Pierson S, Guyonnet L, Viry E, et al
    Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia.
    Blood. 2018 Feb 13. pii: blood-2017-06-792267. doi: 10.1182/blood-2017-06-792267
    PubMed     Text format    


  31. BHAGWAT AS, Lu B, Vakoc CR
    Enhancer dysfunction in leukemia.
    Blood. 2018 Feb 9. pii: blood-2017-11-737379. doi: 10.1182/blood-2017-11-737379.
    PubMed     Text format     Abstract available


  32. ZHANG Y, Gao Y, Zhang H, Zhang J, et al
    PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.
    Blood. 2018 Feb 6. pii: blood-2017-11-817510. doi: 10.1182/blood-2017-11-817510.
    PubMed     Text format     Abstract available


  33. YUN S, Zhang L, Patel MR, Knepper TC, et al
    Transformation of Chronic Lymphocytic Leukemia (CLL) into B-cell Acute Lymphoblastic Leukemia (ALL).
    Blood. 2018 Feb 5. pii: blood-2017-11-819276. doi: 10.1182/blood-2017-11-819276.
    PubMed     Text format    


  34. MURAKAMI N, Okuno Y, Yoshida K, Shiraishi Y, et al
    Integrated molecular profiling of juvenile myelomonocytic leukemia.
    Blood. 2018 Feb 2. pii: blood-2017-07-798157. doi: 10.1182/blood-2017-07-798157.
    PubMed     Text format     Abstract available


  35. O'BRIEN S, Furman RR, Coutre S, Flinn IW, et al
    Single-Agent Ibrutinib in Treatment-Naive and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience.
    Blood. 2018 Feb 2. pii: blood-2017-10-810044. doi: 10.1182/blood-2017-10-810044.
    PubMed     Text format     Abstract available


    January 2018
  36. DINMOHAMED AG, Posthuma EFM, Visser O, Kater AP, et al
    Relative survival reaches a plateau in hairy cell leukemia: a population-based analysis in the Netherlands.
    Blood. 2018 Jan 30. pii: blood-2017-12-820381. doi: 10.1182/blood-2017-12-820381
    PubMed     Text format    


  37. TAKAHASHI K, Hu B, Wang F, Yan Y, et al
    Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.
    Blood. 2018 Jan 22. pii: blood-2017-11-817296. doi: 10.1182/blood-2017-11-817296
    PubMed     Text format     Abstract available


  38. GOKBUGET N, Dombret H, Bonifacio M, Reichle A, et al
    Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia.
    Blood. 2018 Jan 22. pii: blood-2017-08-798322. doi: 10.1182/blood-2017-08-798322
    PubMed     Text format     Abstract available


  39. HANDGRETINGER R, Schilbach K
    The potential role of gammadelta T cells after allogeneic HCT for leukemia.
    Blood. 2018 Jan 22. pii: blood-2017-08-752162. doi: 10.1182/blood-2017-08-752162
    PubMed     Text format     Abstract available


  40. GUTJAHR JC, Szenes E, Tschech L, Asslaber D, et al
    Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.
    Blood. 2018 Jan 19. pii: blood-2017-08-802462. doi: 10.1182/blood-2017-08-802462
    PubMed     Text format     Abstract available


  41. SUN W, Triche T Jr., Malvar J, Gaynon P, et al
    A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from TACL consortium.
    Blood. 2018 Jan 16. pii: blood-2017-09-803809. doi: 10.1182/blood-2017-09-803809
    PubMed     Text format     Abstract available


  42. JANOVSKA P, Verner J, Kohoutek J, Bryjova L, et al
    Casein Kinase 1 is a Therapeutic Target in Chronic Lymphocytic Leukemia.
    Blood. 2018 Jan 9. pii: blood-2017-05-786947. doi: 10.1182/blood-2017-05-786947.
    PubMed     Text format     Abstract available


  43. BRIDE KL, Vincent TL, Im SY, Aplenc R, et al
    Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia (T-ALL).
    Blood. 2018 Jan 5. pii: blood-2017-07-794214. doi: 10.1182/blood-2017-07-794214.
    PubMed     Text format     Abstract available


  44. COUTRE S, Choi M, Furman RR, Eradat H, et al
    Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
    Blood. 2018 Jan 5. pii: blood-2017-06-788133. doi: 10.1182/blood-2017-06-788133.
    PubMed     Text format     Abstract available


  45. LOCKE FL, Anasetti C
    Off-the-shelf TCR for graft-versus-leukemia without GVHD.
    Blood. 2018;131:5-7.
    PubMed     Text format    


  46. MILNE TA
    LEDGF: a leukemia-specific target.
    Blood. 2018;131:4-5.
    PubMed     Text format    


    December 2017
  47. GROCKOWIAK E, Laperrousaz B, Jeanpierre S, Voeltzel T, et al
    Immature CML cells implement a BMP autocrine loop to escape TKI treatment.
    Blood. 2017;130:2860-2871.
    PubMed     Text format     Abstract available


  48. SHIOZAWA Y, Malcovati L, Galli A, Pellagatti A, et al
    Gene expression and risk of leukemic transformation in myelodysplasia.
    Blood. 2017;130:2642-2653.
    PubMed     Text format     Abstract available


  49. PRATS-MARTIN C, Morales-Camacho RM
    Circulating hypergranular neoplastic cells: not always leukemic promyelocytes.
    Blood. 2017;130:2689.
    PubMed     Text format    


  50. YAO L, Wen L, Wang N, Liu T, et al
    Identification of novel recurrent STAT3-RARA fusions in acute promyelocytic leukemia lacking t(15;17)(q22;q12)/PML-RARA.
    Blood. 2017 Dec 13. pii: blood-2017-09-807370. doi: 10.1182/blood-2017-09-807370
    PubMed     Text format    


  51. RAIKAR SS, Park SI, Leong T, Jaye DL, et al
    Isolated myeloperoxidase expression in pediatric B/myeloid mixed phenotype acute leukemia is linked with better survival.
    Blood. 2017 Dec 9. pii: blood-2017-09-807602. doi: 10.1182/blood-2017-09-807602.
    PubMed     Text format    


  52. WEI AH, Tiong IS
    Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
    Blood. 2017;130:2469-2474.
    PubMed     Text format     Abstract available


  53. BOSE P, Konopleva MY
    T-PLL: another check on the venetoclax list?
    Blood. 2017;130:2447-2448.
    PubMed     Text format    


  54. OBSTFELD AE, Frey NV, Mansfield K, Lacey SF, et al
    Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.
    Blood. 2017;130:2569-2572.
    PubMed     Text format    


  55. STEIN EM, Walter RB, Erba HP, Fathi AT, et al
    A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33 positive acute myeloid leukemia (AML).
    Blood. 2017 Dec 1. pii: blood-2017-06-789800. doi: 10.1182/blood-2017-06-789800.
    PubMed     Text format     Abstract available


    November 2017
  56. COOPER JN, Young NS
    Clonality in context: hematopoietic clones in their marrow environment.
    Blood. 2017;130:2363-2372.
    PubMed     Text format     Abstract available


  57. ZHEN T, Kwon EM, Zhao L, Hsu J, et al
    Chd7 deficiency delays leukemogenesis in mice induced by Cbfb-MYH11.
    Blood. 2017;130:2431-2442.
    PubMed     Text format     Abstract available


  58. RASHIDI A, Gilles S
    The unused iron.
    Blood. 2017;130:2445.
    PubMed     Text format    


  59. STRAUBE J, Ling VY, Hill GR, Lane SW, et al
    The impact of age, NPM1(mut) and FLT3(ITD) allelic ratio in patients with acute myeloid leukemia.
    Blood. 2017 Nov 28. pii: blood-2017-09-807438. doi: 10.1182/blood-2017-09-807438
    PubMed     Text format    


  60. JOHNSRUD AJ, Pina-Oviedo S
    Carcinocythemia (carcinoma cell leukemia).
    Blood. 2017;130:2357.
    PubMed     Text format    


  61. CHAI-ADISAKSOPHA C, Brown JR
    FCR achieves long-term durable remissions in patients with IGHV-mutated CLL.
    Blood. 2017;130:2278-2282.
    PubMed     Text format     Abstract available


  62. THAKRAL B, Konoplev S
    "Soccer ball" cells to "donut" cells: an unusual case of Richter syndrome.
    Blood. 2017;130:2358.
    PubMed     Text format    


  63. CRANE GM, Perkins AS
    Leukemic presentation of diffuse large B-cell lymphoma: an unusual pattern associated with splenic involvement.
    Blood. 2017;130:2233.
    PubMed     Text format    


  64. QUESADA AE, Konoplev S
    Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome).
    Blood. 2017;130:2151.
    PubMed     Text format    


  65. HU Z, Konoplev S
    Aleukemic mast cell leukemia associated with chronic myelomonocytic leukemia and chronic lymphocytic leukemia.
    Blood. 2017;130:2150.
    PubMed     Text format    


  66. ISSA GC, Kantarjian HM, Gonzalez GN, Borthakur G, et al
    Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment.
    Blood. 2017;130:2084-2091.
    PubMed     Text format     Abstract available


  67. HEHLMANN R
    Prognostic relevance of CCAs/Ph(-) in CML settled.
    Blood. 2017;130:2046-2047.
    PubMed     Text format    


  68. LOCATELLI F, Valsecchi MG, Moricke A, Zimmermann M, et al
    Protocol II vs protocol III given twice during reinduction therapy in children with medium-risk ALL.
    Blood. 2017;130:2146-2149.
    PubMed     Text format    


  69. SERAFIN V, Capuzzo G, Milani G, Minuzzo SA, et al
    Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
    Blood. 2017 Nov 3. pii: blood-2017-05-784603. doi: 10.1182/blood-2017-05-784603.
    PubMed     Text format     Abstract available


  70. TAWARA I, Kageyama S, Miyahara Y, Fujiwara H, et al
    Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.
    Blood. 2017;130:1985-1994.
    PubMed     Text format     Abstract available


    October 2017
  71. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    Chronic lymphocytic leukemia international prognostic index (CLL-IPI): a systematic review and meta-analysis.
    Blood. 2017 Oct 30. pii: blood-2017-09-806034. doi: 10.1182/blood-2017-09-806034
    PubMed     Text format    


  72. KATAOKA K, Iwanaga M, Yasunaga JI, Nagata Y, et al
    Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.
    Blood. 2017 Oct 30. pii: blood-2017-01-761874. doi: 10.1182/blood-2017-01-761874
    PubMed     Text format     Abstract available


  73. FALINI B, Sportoletti P
    A scale of "bad" co-mutations in NPM1-driven AML.
    Blood. 2017;130:1877-1879.
    PubMed     Text format    


  74. BOUVIER S, Martin M
    Atypical monoblasts with micronuclei.
    Blood. 2017;130:1958.
    PubMed     Text format    


  75. GILLISSEN MA, Kedde M, de Jong G, Moiset G, et al
    AML-specific cytotoxic antibodies in patients with durable graft versus leukemia responses.
    Blood. 2017 Oct 23. pii: blood-2017-02-768762. doi: 10.1182/blood-2017-02-768762
    PubMed     Text format     Abstract available


  76. DOSSA RG, Cunningham T, Sommermeyer D, Medina-Rodriguez I, et al
    Development of T cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse.
    Blood. 2017 Oct 19. pii: blood-2017-07-791608. doi: 10.1182/blood-2017-07-791608
    PubMed     Text format     Abstract available


  77. PETIT A, Trinquand A, Chevret S, Ballerini P, et al
    Oncogenetic mutations combined with MRD improve outcome prediction in pediatric T-Cell Acute Lymphoblastic Leukemia.
    Blood. 2017 Oct 19. pii: blood-2017-04-778829. doi: 10.1182/blood-2017-04-778829
    PubMed     Text format     Abstract available


  78. TIAO G, Improgo MR, Tausch E, Fernandes SM, et al
    Analysis of ITGB2 rare germline variants in chronic lymphocytic leukemia.
    Blood. 2017 Oct 19. pii: blood-2017-08-800128. doi: 10.1182/blood-2017-08-800128
    PubMed     Text format    


  79. HARANKHEDKAR S, Gupta R
    MPO-negative inclusions and Auer rod-like structures in a case of acute myeloid leukemia with t(8;21).
    Blood. 2017;130:1869.
    PubMed     Text format    


  80. RUTHERFORD SC, Leonard JP
    Lymphoma "benchmark" or "bench-smudge"?
    Blood. 2017;130:1778-1779.
    PubMed     Text format    


  81. ODA SK, Daman AW, Garcia NM, Wagener F, et al
    A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T cell function and therapy of murine leukemia.
    Blood. 2017 Oct 17. pii: blood-2017-04-777052. doi: 10.1182/blood-2017-04-777052
    PubMed     Text format     Abstract available


  82. SANDA T
    RUNX1 in T-ALL: tumor suppressive or oncogenic?
    Blood. 2017;130:1686-1688.
    PubMed     Text format    


  83. XU Z
    AML with myelodysplasia-related changes masquerades as acute panmyelosis with myelofibrosis.
    Blood. 2017;130:1775.
    PubMed     Text format    


  84. APPELBAUM FR, Bernstein ID
    Gemtuzumab ozogamicin for acute myeloid leukemia.
    Blood. 2017 Oct 11. pii: blood-2017-09-797712. doi: 10.1182/blood-2017-09-797712
    PubMed     Text format     Abstract available


  85. MAR BG, Chu SH, Kahn JD, Krivstov AV, et al
    SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.
    Blood. 2017 Oct 10. pii: blood-2017-03-775569. doi: 10.1182/blood-2017-03-775569
    PubMed     Text format     Abstract available


  86. WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
    Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
    Blood. 2017;130:1620-1627.
    PubMed     Text format     Abstract available


  87. BOBROWICZ M, Dwojak M, Pyrzynska B, Stachura J, et al
    HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies.
    Blood. 2017;130:1628-1638.
    PubMed     Text format     Abstract available


  88. MARLEIN CR, Zaitseva L, Piddock RE, Robinson SD, et al
    NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts.
    Blood. 2017;130:1649-1660.
    PubMed     Text format     Abstract available


  89. WONG RWJ, Ngoc PCT, Leong WZ, Yam AWY, et al
    Enhancer profiling identifies critical cancer genes and characterizes cell identity in adult T-cell leukemia.
    Blood. 2017 Oct 4. pii: blood-2017-06-792184. doi: 10.1182/blood-2017-06-792184.
    PubMed     Text format     Abstract available


  90. TASIAN SK, Loh ML, Hunger SP
    Philadelphia chromosome-like acute lymphoblastic leukemia.
    Blood. 2017 Oct 2. pii: blood-2017-06-743252. doi: 10.1182/blood-2017-06-743252.
    PubMed     Text format     Abstract available


    September 2017
  91. THAKRAL B, Wang SA
    "Hof" in pronormoblasts: pure erythroid leukemia mimicking plasma cell myeloma.
    Blood. 2017;130:1600.
    PubMed     Text format    


  92. KARAESMEN E, Rizvi AA, Preus LM, McCarthy PL, et al
    Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.
    Blood. 2017;130:1585-1596.
    PubMed     Text format     Abstract available


  93. JABBOUR E, Short NJ, Montalban-Bravo G, Huang X, et al
    Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.
    Blood. 2017;130:1514-1522.
    PubMed     Text format     Abstract available


  94. ADVANI AS
    "MOR" engineering of antibodies in ALL.
    Blood. 2017;130:1487-1488.
    PubMed     Text format    


  95. BOIDOL B, Kornauth C, van der Kouwe E, Prutsch N, et al
    First in human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
    Blood. 2017 Sep 27. pii: blood-2017-05-785683. doi: 10.1182/blood-2017-05-785683
    PubMed     Text format     Abstract available


  96. MUELLER KT, Maude SL, Porter DL, Frey N, et al
    Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
    Blood. 2017 Sep 21. pii: blood-2017-06-786129. doi: 10.1182/blood-2017-06-786129
    PubMed     Text format     Abstract available


  97. SHEA TC
    Are outcomes of allografts for CLL still relevant?
    Blood. 2017;130:1393-1394.
    PubMed     Text format    


  98. ZHENG L, Hu S
    Philadelphia chromosome-positive B-lymphoblastic lymphoma involving the genitourinary system and bone at initial diagnosis and relapse.
    Blood. 2017;130:1483.
    PubMed     Text format    


  99. KRAMER I, Stilgenbauer S, Dietrich S, Bottcher S, et al
    Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial.
    Blood. 2017;130:1477-1480.
    PubMed     Text format    


  100. ZURLI V, Wimmer G, Cattaneo F, Candi V, et al
    Ectopic ILT3 controls BCR-dependent activation of Akt in B-cell chronic lymphocytic leukemia.
    Blood. 2017 Sep 20. pii: blood-2017-03-775858. doi: 10.1182/blood-2017-03-775858
    PubMed     Text format     Abstract available


  101. WANG HY, Feldman AL
    Exuberant nodal proliferation of mature plasmacytoid dendritic cells in a patient with chronic myelomonocytic leukemia.
    Blood. 2017;130:1387.
    PubMed     Text format    


  102. LIN S, Ptasinska A, Chen X, Shrestha M, et al
    A FOXO1-induced oncogenic network defines the AML1-ETO preleukemic program.
    Blood. 2017;130:1213-1222.
    PubMed     Text format     Abstract available


  103. ASEMISSEN AM, Dierlamm J
    The beauty and the beast: lymphoma-like morphology of myeloid blast phase in CML.
    Blood. 2017;130:1274.
    PubMed     Text format    


  104. AHCI M, Toffalori C, Bouwmans E, Crivello P, et al
    A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT.
    Blood. 2017;130:1270-1273.
    PubMed     Text format    


    August 2017
  105. BAZARBACHI A
    CDK9 inhibition for ATL therapy.
    Blood. 2017;130:1074-1075.
    PubMed     Text format    


  106. LEHNERTZ B, Zhang YW, Boivin I, Mayotte N, et al
    H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations.
    Blood. 2017 Aug 30. pii: blood-2017-03-774653. doi: 10.1182/blood-2017-03-774653
    PubMed     Text format     Abstract available


  107. DOVEY OM, Cooper JL, Mupo A, Grove CS, et al
    Molecular synergy underlies the co-occurrence patterns and phenotype of NPM1-mutant acute myeloid leukemia.
    Blood. 2017 Aug 23. pii: blood-2017-01-760595. doi: 10.1182/blood-2017-01-760595
    PubMed     Text format     Abstract available


  108. BRUNSON A, Keegan THM, Bang H, Mahajan A, et al
    Increased risk of leukemia among sickle cell disease patients in California.
    Blood. 2017 Aug 22. pii: blood-2017-05-783233. doi: 10.1182/blood-2017-05-783233
    PubMed     Text format    


  109. ANGUILLE S, Van de Velde AL, Smits EL, Van Tendeloo VF, et al
    Dendritic cell vaccination as post-remission treatment to prevent or delay relapse in acute myeloid leukemia.
    Blood. 2017 Aug 22. pii: blood-2017-04-780155. doi: 10.1182/blood-2017-04-780155
    PubMed     Text format     Abstract available


  110. NAGEL I, Bartels M, Duell J, Oberg HH, et al
    Hematopoietic stem cell involvement in BCR-ABL1-positive ALL as potential mechanism of resistance to blinatumomab therapy.
    Blood. 2017 Aug 21. pii: blood-2017-05-782888. doi: 10.1182/blood-2017-05-782888
    PubMed     Text format     Abstract available


  111. ZHOU XY, Behdad A
    Relapse of an acute leukemia of mixed lineage as an isolated orbital mass.
    Blood. 2017;130:953.
    PubMed     Text format    


  112. KATAYAMA S, Suzuki M, Yamaoka A, Keleku-Lukwete N, et al
    GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Blood. 2017;130:908-919.
    PubMed     Text format     Abstract available


  113. MAGINA KN, Pregartner G, Zebisch A, Wolfler A, et al
    Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis.
    Blood. 2017;130:946-948.
    PubMed     Text format    


  114. DURHAM BH, Getta B, Dietrich S, Taylor J, et al
    Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
    Blood. 2017 Aug 11. pii: blood-2017-01-765107. doi: 10.1182/blood-2017-01-765107
    PubMed     Text format     Abstract available


  115. KARJALAINEN R, Pemovska T, Popa M, Liu M, et al
    JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.
    Blood. 2017;130:789-802.
    PubMed     Text format     Abstract available


  116. WOUTERS BJ
    Hitting the target in IDH2 mutant AML.
    Blood. 2017;130:693-694.
    PubMed     Text format    


  117. SELIMOGLU-BUET D, Badaoui B, Benayoun E, Toma A, et al
    Accumulation of classical monocytes defines a subgroup of MDS that frequently evolves into CMML.
    Blood. 2017;130:832-835.
    PubMed     Text format    


  118. WAYNE AS, Shah NN, Bhojwani D, Silverman LB, et al
    Phase I Study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.
    Blood. 2017 Aug 9. pii: blood-2017-02-749101. doi: 10.1182/blood-2017-02-749101.
    PubMed     Text format     Abstract available


  119. CHOI A, Illendula A, Pulikkan JA, Roderick JE, et al
    RUNX1 is required for oncogenic Myb and Myc enhancer activity in T cell acute lymphoblastic leukemia.
    Blood. 2017 Aug 8. pii: blood-2017-03-775536. doi: 10.1182/blood-2017-03-775536.
    PubMed     Text format     Abstract available


  120. LAFAGE-POCHITALOFF M, Baranger L, Hunault M, Cuccuini W, et al
    Value of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.
    Blood. 2017 Aug 8. pii: blood-2017-05-783852. doi: 10.1182/blood-2017-05-783852.
    PubMed     Text format     Abstract available


  121. MIZUKAWA B, O'Brien E, Moreira DC, Wunderlich M, et al
    Cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.
    Blood. 2017 Aug 4. pii: blood-2016-12-758458. doi: 10.1182/blood-2016-12-758458.
    PubMed     Text format     Abstract available


  122. LILLJEBJORN H, Fioretos T
    New oncogenic subtypes in pediatric B-cell precursor acute lymphoblastic leukemia.
    Blood. 2017 Aug 4. pii: blood-2017-05-742643. doi: 10.1182/blood-2017-05-742643.
    PubMed     Text format     Abstract available


  123. ARRANTO C, Tzankov A
    Broken heart by T-prolymphocytic leukemia.
    Blood. 2017;130:691.
    PubMed     Text format    


  124. IZRAELI S, Eckert C
    Targeted therapy of CNS leukemia?
    Blood. 2017;130:562-563.
    PubMed     Text format    


  125. CARTRON G, Watier H
    Obinutuzumab: what is there to learn from clinical trials?
    Blood. 2017;130:581-589.
    PubMed     Text format     Abstract available


    July 2017
  126. WALLACE JA, O'Connell RM
    MicroRNAs and acute myeloid leukemia: therapeutic implications and emerging concepts.
    Blood. 2017 Jul 27. pii: blood-2016-10-697698. doi: 10.1182/blood-2016-10-697698
    PubMed     Text format     Abstract available


  127. GODLEY LA, Shimamura A
    Genetic predisposition to hematologic malignancies: management and surveillance.
    Blood. 2017;130:424-432.
    PubMed     Text format     Abstract available


  128. YOSHIMI A, Balasis ME, Vedder A, Feldman K, et al
    Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.
    Blood. 2017;130:397-407.
    PubMed     Text format     Abstract available


  129. RAU RE
    CMML/JMML PDXs: as easy as 1, 2, NSG-SGM3.
    Blood. 2017;130:385-386.
    PubMed     Text format    


  130. DONG L, Zheng H, Qu CK
    CCL3 is a key mediator for the leukemogenic effect of Ptpn11 activating mutations in the stem cell microenvironment.
    Blood. 2017 Jul 27. pii: blood-2017-06-791103. doi: 10.1182/blood-2017-06-791103
    PubMed     Text format    


  131. TOBOSO DG, Campos CB
    Peripheral eosinophilia as the first manifestation of B-cell acute lymphoblastic leukemia with t(5;14)(q31;q32).
    Blood. 2017;130:380.
    PubMed     Text format    


  132. GOMES-SILVA D, Srinivasan M, Sharma S, Lee CM, et al
    CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies.
    Blood. 2017;130:285-296.
    PubMed     Text format     Abstract available


  133. AL SAYED MF, Ruckstuhl CA, Hilmenyuk T, Claus C, et al
    CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
    Blood. 2017;130:297-309.
    PubMed     Text format     Abstract available



  134. Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129(19):2702-2705.
    Blood. 2017;130:232.
    PubMed     Text format    


  135. THAKRAL B, Muzzafar T
    Diagnosing therapy-related acute myeloid leukemia with 8% blasts in bone marrow with concomitant plasma cell myeloma.
    Blood. 2017;130:231.
    PubMed     Text format    


  136. TALSMA CE, Boyer DF
    Myeloid leukemia associated with Down syndrome.
    Blood. 2017;130:230.
    PubMed     Text format    


  137. AGATHANGGELOU A, Smith E, Davies NJ, Kwok M, et al
    USP7 inhibition alters homologous recombination repair and targets CLL cells independently of ATM/p53 functional status.
    Blood. 2017;130:156-166.
    PubMed     Text format     Abstract available


  138. SAMPATH D
    Targeting deubiquitinases in CLL.
    Blood. 2017;130:100-101.
    PubMed     Text format    


  139. PILLAI V, Maude SL
    CART attack.
    Blood. 2017;130:229.
    PubMed     Text format    


  140. SCHEWE DM, Alsadeq A, Sattler C, Lenk L, et al
    An Fc engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts.
    Blood. 2017 Jul 11. pii: blood-2017-01-764316. doi: 10.1182/blood-2017-01-764316
    PubMed     Text format     Abstract available


  141. CARPENTER PA, Johnston L, Fernandez HF, Radich JP, et al
    Post-transplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia.
    Blood. 2017 Jul 11. pii: blood-2017-03-771121. doi: 10.1182/blood-2017-03-771121
    PubMed     Text format    


  142. BLACKBURN NB, Marthick JR, Banks A, Charlesworth JC, et al
    Evaluating a CLL susceptibility variant in ITGB2 in families with multiple subtypes of hematological malignancies.
    Blood. 2017;130:86-88.
    PubMed     Text format    


  143. KITAMURA N, Nakanishi T, Yoshida Y, Higashi T, et al
    HTLV-I-associated posttransplant lymphoproliferative disorder following virus transmission from recipient to donor cells.
    Blood. 2017;130:84-86.
    PubMed     Text format    


    June 2017
  144. QUESADA AE, Kanagal-Shamanna R
    Targeted therapy-induced differentiation of acute myeloid leukemia blasts.
    Blood. 2017;129:3503.
    PubMed     Text format    


  145. LEVIS M
    Midostaurin approved for FLT3-mutated AML.
    Blood. 2017;129:3403-3406.
    PubMed     Text format     Abstract available


  146. CHAUDHRY P, Singh M, Triche TJ, Guzman M, et al
    GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML.
    Blood. 2017;129:3465-3475.
    PubMed     Text format     Abstract available


  147. PAGEL JM
    A Richter transformation PD-1 block party.
    Blood. 2017;129:3397-3398.
    PubMed     Text format    


  148. RIGOLIN GM, Cavallari M, Quaglia FM, Formigaro L, et al
    In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI.
    Blood. 2017;129:3495-3498.
    PubMed     Text format    


  149. MORIYAMA T, Yang YL, Nishii R, Ariffin H, et al
    Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry.
    Blood. 2017 Jun 28. pii: blood-2017-05-782383. doi: 10.1182/blood-2017-05-782383
    PubMed     Text format     Abstract available


  150. NARITA T, Ishida T, Ito A, Masaki A, et al
    Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Blood. 2017 Jun 23. pii: blood-2016-09-741983. doi: 10.1182/blood-2016-09-741983
    PubMed     Text format     Abstract available


  151. BRIERLEY CK, Eyre TA
    Acute monoblastic leukemia presenting with striking periorbital and periauricular infiltration.
    Blood. 2017;129:3396.
    PubMed     Text format    


  152. ANDERSON MA, Tam C, Lew TE, Juneja S, et al
    Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.
    Blood. 2017;129:3362-3370.
    PubMed     Text format     Abstract available


  153. MALCOVATI L, Galli A, Travaglino E, Ambaglio I, et al
    Clinical significance of somatic mutation in unexplained blood cytopenia.
    Blood. 2017;129:3371-3378.
    PubMed     Text format     Abstract available


  154. RESHMI SC, Harvey RC, Roberts KG, Stonerock E, et al
    Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group.
    Blood. 2017;129:3352-3361.
    PubMed     Text format     Abstract available


  155. TOMIZAWA D, Kolb EA
    Down syndrome and AML: where do we go from here?
    Blood. 2017;129:3274-3275.
    PubMed     Text format    


  156. SHAND JC
    Looking up for AML in Down syndrome.
    Blood. 2017;129:3273-3274.
    PubMed     Text format    


  157. GRIBBEN JG
    Restoring leukemia cell function from the inside out.
    Blood. 2017;129:3137-3138.
    PubMed     Text format    


  158. GOOSSENS S, Van Vlierberghe P
    Novel oncogenic noncoding mutations in T-ALL.
    Blood. 2017;129:3140-3142.
    PubMed     Text format    


  159. GARRISON BS, Rybak AP, Beerman I, Heesters B, et al
    ZFP521 regulates murine hematopoietic stem cell function and facilitates MLL-AF9 leukemogenesis in mouse and human cells.
    Blood. 2017 Jun 14. pii: blood-2016-09-738591. doi: 10.1182/blood-2016-09-738591
    PubMed     Text format     Abstract available


  160. PROKOCIMER M, Molchadsky A, Rotter V
    Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic work-up and therapy.
    Blood. 2017 Jun 12. pii: blood-2017-02-763086. doi: 10.1182/blood-2017-02-763086
    PubMed     Text format     Abstract available


  161. PRIETO D, Sotelo N, Seija N, Sernbo S, et al
    S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-kappaB activity during disease progression.
    Blood. 2017 Jun 8. pii: blood-2017-02-769851. doi: 10.1182/blood-2017-02-769851.
    PubMed     Text format     Abstract available


  162. WALLACE JA, Kagele DA, Eiring AM, Kim CN, et al
    miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response.
    Blood. 2017;129:3074-3086.
    PubMed     Text format     Abstract available


  163. RASHIDI A, Courville EL
    Double-heart sign.
    Blood. 2017;129:3134.
    PubMed     Text format    


  164. KATO I, Nishinaka Y, Nakamura M, Akarca AU, et al
    Hypoxic adaptation of leukemic cells infiltrating the CNS affords a therapeutic strategy targeting VEGFA.
    Blood. 2017;129:3126-3129.
    PubMed     Text format    


  165. STEIN EM, DiNardo CD, Pollyea DA, Fathi AT, et al
    Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia.
    Blood. 2017 Jun 6. pii: blood-2017-04-779405. doi: 10.1182/blood-2017-04-779405.
    PubMed     Text format     Abstract available


  166. AMATANGELO MD, Quek L, Shih A, Stein EM, et al
    Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
    Blood. 2017 Jun 6. pii: blood-2017-04-779447. doi: 10.1182/blood-2017-04-779447.
    PubMed     Text format     Abstract available


  167. LOCATELLI F, Merli P, Pagliara D, Li Pira G, et al
    Outcome of children with acute leukemia given HLA-haploidentical HSCT after alphabeta T-cell and B-cell depletion.
    Blood. 2017 Jun 6. pii: blood-2017-04-779769. doi: 10.1182/blood-2017-04-779769.
    PubMed     Text format     Abstract available


  168. CHELONI G, Tanturli M, Tusa I, DeSouza NH, et al
    Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.
    Blood. 2017 Jun 2. pii: blood-2016-10-745588. doi: 10.1182/blood-2016-10-745588.
    PubMed     Text format     Abstract available


  169. SOLARY E, Itzykson R
    How I treat chronic myelomonocytic leukemia.
    Blood. 2017 Jun 1. pii: blood-2017-04-736421. doi: 10.1182/blood-2017-04-736421.
    PubMed     Text format     Abstract available


    May 2017
  170. MUNCH V, Trentin L, Herzig J, Demir S, et al
    Central Nervous System Involvement in Acute Lymphoblastic Leukemia Is Mediated by Vascular Endothelial Growth Factor.
    Blood. 2017 May 26. pii: blood-2017-03-769315. doi: 10.1182/blood-2017-03-769315
    PubMed     Text format     Abstract available


  171. MAN N, Tan Y, Sun XJ, Liu F, et al
    Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner.
    Blood. 2017;129:2782-2792.
    PubMed     Text format     Abstract available


  172. HOVORKOVA L, Zaliova M, Venn NC, Bleckmann K, et al
    Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology.
    Blood. 2017;129:2771-2781.
    PubMed     Text format     Abstract available


  173. HUNGER SP
    CML in blast crisis: more common than we think?
    Blood. 2017;129:2713-2714.
    PubMed     Text format    


  174. WALTER HS, Jayne S, Rule SA, Cartron G, et al
    Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
    Blood. 2017;129:2808-2810.
    PubMed     Text format    


  175. KATSUYA H, Shimokawa M, Ishitsuka K, Kawai K, et al
    A prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma.
    Blood. 2017 May 17. pii: blood-2017-01-757542. doi: 10.1182/blood-2017-01-757542
    PubMed     Text format     Abstract available


  176. CHEN TL, Tran M, Lakshmanan A, Harrington BK, et al
    NF-kappaB p50 (nfkb1) contributes to pathogenesis in the Emu-TCL1 mouse model of chronic lymphocytic leukemia.
    Blood. 2017 May 17. pii: blood-2017-01-761130. doi: 10.1182/blood-2017-01-761130
    PubMed     Text format    


  177. BARR PM, Brown JR, Hillmen P, O'Brien S, et al
    Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
    Blood. 2017;129:2612-2615.
    PubMed     Text format     Abstract available


  178. VALGARDSDOTTIR R, Cattaneo I, Klein C, Introna M, et al
    Human neutrophils mediate trogocytosis rather than phagocytosis of CLL B cells opsonized with anti-CD20 antibodies.
    Blood. 2017;129:2636-2644.
    PubMed     Text format     Abstract available


  179. LIYANAGE SU, Hurren R, Voisin V, Bridon G, et al
    Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
    Blood. 2017;129:2657-2666.
    PubMed     Text format     Abstract available


  180. WANG HY, Hodkoff A
    Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology.
    Blood. 2017;129:2711.
    PubMed     Text format    


  181. PINTON P
    A mitochondrial drug to treat AML.
    Blood. 2017;129:2597-2599.
    PubMed     Text format    


  182. SMITH CC, Paguirigan A, Jeschke GR, Lin KC, et al
    Heterogeneous resistance to quizartinib in acute myeloid leukemia (AML) revealed by single cell analysis.
    Blood. 2017 May 10. pii: blood-2016-04-711820. doi: 10.1182/blood-2016-04-711820
    PubMed     Text format     Abstract available


  183. XU J, Li S
    Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia.
    Blood. 2017;129:2593.
    PubMed     Text format    


  184. DOURADO KMC, Baik J, Oliveira VKP, Beltrame M, et al
    Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.
    Blood. 2017;129:2526-2536.
    PubMed     Text format     Abstract available


  185. WANG HY
    Large B-cell lymphoma variant of Richter transformation originates in pseudoproliferation centers of small lymphocytic lymphoma.
    Blood. 2017;129:2592.
    PubMed     Text format    


  186. LAMPSON BL, Yu L, Glynn RJ, Barrientos JC, et al
    Ventricular arrhythmias and sudden death in patients taking ibrutinib.
    Blood. 2017;129:2581-2584.
    PubMed     Text format    


  187. GORINI F, Azzimonti L, Delfanti G, Scarfo L, et al
    Invariant NKT cells contribute to chronic lymphocytic leukemia surveillance and prognosis.
    Blood. 2017 May 2. pii: blood-2016-11-751065. doi: 10.1182/blood-2016-11-751065.
    PubMed     Text format     Abstract available


    April 2017
  188. PARILLA M, Venkataraman G
    The thin line between CML and CMML.
    Blood. 2017;129:2456.
    PubMed     Text format    


  189. RADICH J
    Understanding CML, 1 cell at a time.
    Blood. 2017;129:2339-2340.
    PubMed     Text format    


  190. KRUTH K, Fang M, Shelton DN, Abu-Halawa O, et al
    Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
    Blood. 2017 Apr 19. pii: blood-2017-02-766204. doi: 10.1182/blood-2017-02-766204
    PubMed     Text format     Abstract available


  191. DING W, LaPlant BR, Call TG, Parikh SA, et al
    Pembrolizumab in patients with chronic lymphocytic leukemia with Richter's transformation and relapsed CLL.
    Blood. 2017 Apr 19. pii: blood-2017-02-765685. doi: 10.1182/blood-2017-02-765685
    PubMed     Text format     Abstract available


  192. VUJKOVIC M, Attiyeh EF, Ries RE, Goodman EK, et al
    Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
    Blood. 2017 Apr 14. pii: blood-2017-03-772384. doi: 10.1182/blood-2017-03-772384
    PubMed     Text format     Abstract available


  193. GARDNER RA, Finney O, Annesley C, Brakke H, et al
    Intent to treat leukemia remission by CD19CAR T cells of defined formulation and dose in children and young adults.
    Blood. 2017 Apr 13. pii: blood-2017-02-769208. doi: 10.1182/blood-2017-02-769208
    PubMed     Text format     Abstract available


  194. HU S, Qian M, Zhang H, Guo Y, et al
    Whole-genome non-coding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations.
    Blood. 2017 Apr 13. pii: blood-2017-03-771162. doi: 10.1182/blood-2017-03-771162
    PubMed     Text format    



  195. Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129(9):1134-1142.
    Blood. 2017;129:2204.
    PubMed     Text format    


  196. PORCHER C, Chagraoui H, Kristiansen MS
    SCL/TAL1: a multifaceted regulator from blood development to disease.
    Blood. 2017;129:2051-2060.
    PubMed     Text format     Abstract available


  197. SOOD R, Kamikubo Y, Liu P
    Role of RUNX1 in hematological malignancies.
    Blood. 2017;129:2070-2082.
    PubMed     Text format     Abstract available


  198. AVELLINO R, Delwel R
    Expression and regulation of C/EBPalpha in normal myelopoiesis and in malignant transformation.
    Blood. 2017;129:2083-2091.
    PubMed     Text format     Abstract available


  199. DE BRUIJN M, Dzierzak E
    Runx transcription factors in the development and function of the definitive hematopoietic system.
    Blood. 2017;129:2061-2069.
    PubMed     Text format     Abstract available


  200. UFFMANN M, Rasche M, Zimmermann M, von Neuhoff C, et al
    Therapy reduction in patients with Down Syndrome Myeloid Leukemia: The international ML-DS 2006 trial.
    Blood. 2017 Apr 11. pii: blood-2017-01-765057. doi: 10.1182/blood-2017-01-765057
    PubMed     Text format     Abstract available


  201. BELDERBOS ME, Koster T, Ausema B, Jacobs S, et al
    Clonal selection and asymmetric distribution of human leukemia in murine xenografts revealed by cellular barcoding.
    Blood. 2017 Apr 10. pii: blood-2016-12-758250. doi: 10.1182/blood-2016-12-758250
    PubMed     Text format     Abstract available


  202. TAUB JW, Berman JN, Hitzler JK, Sorrell AD, et al
    Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.
    Blood. 2017 Apr 7. pii: blood-2017-01-764324. doi: 10.1182/blood-2017-01-764324.
    PubMed     Text format     Abstract available


  203. LANDIER W, Chen Y, Hageman L, Kim H, et al
    Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study.
    Blood. 2017;129:1919-1926.
    PubMed     Text format     Abstract available


  204. DOWSE RT, Ireland RM
    Variant ZBTB16-RARA translocation: morphological changes predict cytogenetic variants of APL.
    Blood. 2017;129:2038.
    PubMed     Text format    


    March 2017
  205. GO RS, Winters JL, Kay NE
    How I treat autoimmune hemolytic anemia.
    Blood. 2017 Mar 30. pii: blood-2016-11-693689. doi: 10.1182/blood-2016-11-693689
    PubMed     Text format     Abstract available


  206. GREENBERG PL
    The classical nature of distinctive CMML monocytes.
    Blood. 2017;129:1745-1746.
    PubMed     Text format    


  207. FALANGA A
    Predicting APL lethal bleeding in the ATRA era.
    Blood. 2017;129:1739-1740.
    PubMed     Text format    


  208. TALATI C, Zhang L, Shaheen G, Kuykendall A, et al
    Monocyte subset analysis accurately distinguishes CMML from MDS and is associated with a favorable MDS prognosis.
    Blood. 2017;129:1881-1883.
    PubMed     Text format    


  209. GEYER MB, Hsu M, Devlin SM, Tallman MS, et al
    Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis.
    Blood. 2017;129:1878-1881.
    PubMed     Text format    


  210. BACHEGOWDA LS, Saliba RM, Ramlal R, Kongtim P, et al
    Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation.
    Blood. 2017 Mar 28. pii: blood-2017-02-766154. doi: 10.1182/blood-2017-02-766154
    PubMed     Text format    


  211. GARZON R, Savona M, Baz R, Andreeff M, et al
    A phase I clinical trial of single-agent selinexor in acute myeloid leukemia.
    Blood. 2017 Mar 23. pii: blood-2016-11-750158. doi: 10.1182/blood-2016-11-750158
    PubMed     Text format     Abstract available


  212. FISCHER K, Al-Sawaf O, Fink AM, Dixon M, et al
    Venetoclax and obinutuzumab in chronic lymphocytic leukemia.
    Blood. 2017 Mar 21. pii: blood-2017-01-761973. doi: 10.1182/blood-2017-01-761973
    PubMed     Text format    


  213. CHENG CK, Wang AZ, Wong TH, Wan TS, et al
    FNDC3B is another novel partner fused to RARA in the t(3;17)(q26;q21) variant of acute promyelocytic leukemia.
    Blood. 2017 Mar 17. pii: blood-2017-02-767707. doi: 10.1182/blood-2017-02-767707
    PubMed     Text format    


  214. LOGHAVI S, Khoury JD
    Langerhans cell histiocytosis in a patient with hairy cell leukemia: a tale of divergence.
    Blood. 2017;129:1563.
    PubMed     Text format    


  215. FRISMANTAS V, Dobay MP, Rinaldi A, Tchinda J, et al
    Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
    Blood. 2017;129:e26-e37.
    PubMed     Text format     Abstract available


  216. WONG TN, Link DC
    miR-125b promotes leukemogenesis via VEGFA.
    Blood. 2017;129:1409-1410.
    PubMed     Text format    


  217. MERTENS D, Stilgenbauer S
    Ibrutinib-resistant CLL: unwanted and unwonted!
    Blood. 2017;129:1407-1409.
    PubMed     Text format    


  218. HEIN N, Cameron DP, Hannan KM, Nguyen NN, et al
    Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
    Blood. 2017 Mar 10. pii: blood-2016-05-718171. doi: 10.1182/blood-2016-05-718171
    PubMed     Text format     Abstract available


  219. SHAFAT MS, Oellerich T, Mohr S, Robinson SD, et al
    Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment.
    Blood. 2017;129:1320-1332.
    PubMed     Text format     Abstract available


  220. SCHURINGA JJ
    Smart niche usage: release its fat and burn it!
    Blood. 2017;129:1239-1240.
    PubMed     Text format    


  221. DUNCAVAGE EJ, Uy GL, Petti AA, Miller CA, et al
    Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.
    Blood. 2017;129:1397-1401.
    PubMed     Text format    


  222. RAHMAN S, Magnussen M, Leon TE, Farah N, et al
    Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.
    Blood. 2017 Mar 7. pii: blood-2016-09-742148. doi: 10.1182/blood-2016-09-742148.
    PubMed     Text format     Abstract available


  223. LAL R, Lind K, Heitzer E, Ulz P, et al
    Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia.
    Blood. 2017 Mar 3. pii: blood-2016-11-751008. doi: 10.1182/blood-2016-11-751008.
    PubMed     Text format    


  224. GIRARDI T, Vicente C, Cools J, De Keersmaecker K, et al
    The genetics and molecular biology of T-ALL.
    Blood. 2017;129:1113-1123.
    PubMed     Text format     Abstract available


  225. HUGHES A, Clarson J, Tang C, Vidovic L, et al
    CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
    Blood. 2017;129:1166-1176.
    PubMed     Text format     Abstract available


  226. KNAPPER S, Russell N, Gilkes A, Hills RK, et al
    A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML.
    Blood. 2017;129:1143-1154.
    PubMed     Text format     Abstract available


  227. SCHEINBERG DA
    Immune reconstitution and remission in CML.
    Blood. 2017;129:1064-1065.
    PubMed     Text format    


  228. STONE RM
    3 + 7 + FLT3 inhibitors: 1 + 1 not equal 2.
    Blood. 2017;129:1061-1062.
    PubMed     Text format    


  229. ALDOSS I, Song JY
    Donor-derived myeloid neoplasm post allogeneic hematopoietic cell transplantation.
    Blood. 2017;129:1231.
    PubMed     Text format    


  230. SEHN LH, Soulier J
    Introduction to the review series on T-cell malignancies.
    Blood. 2017;129:1059-1060.
    PubMed     Text format    


  231. LECLERC M, Peffault de Latour R, Michallet M, Blaise D, et al
    Can a reduced-intensity conditioning regimen cure blastic plasmacytoid dendritic cell neoplasm?
    Blood. 2017;129:1227-1230.
    PubMed     Text format    


    February 2017
  232. TASIAN SK, Kenderian SS, Shen F, Ruella M, et al
    Optimized Depletion of Chimeric Antigen Receptor T-Cells in Murine Xenograft Models of Human Acute Myeloid Leukemia.
    Blood. 2017 Feb 28. pii: blood-2016-08-736041. doi: 10.1182/blood-2016-08-736041
    PubMed     Text format     Abstract available


  233. MONTALBAN-BRAVO G, Benton CB, Wang SA, Ravandi F, et al
    Greater than one TP53 abnormality is a dominant characteristic of pure erythroid leukemia.
    Blood. 2017 Feb 28. pii: blood-2016-11-749903. doi: 10.1182/blood-2016-11-749903
    PubMed     Text format    


  234. DANESHBOD Y, Medeiros LJ
    Dermal myeloid sarcoma as an initial presentation of acute myeloid leukemia.
    Blood. 2017;129:1056.
    PubMed     Text format    


  235. NAUDIN C, Hattabi A, Michelet F, Miri-Nezhad A, et al
    PUMILIO/FOXP1 signaling drives expansion of hematopoietic stem/progenitor and leukemia cells.
    Blood. 2017 Feb 23. pii: blood-2016-10-747436. doi: 10.1182/blood-2016-10-747436
    PubMed     Text format     Abstract available


  236. AGARWAL P, Zhang B, Ho Y, Cook A, et al
    Enhanced targeting of CML stem and progenitor cells by inhibition of porcupine acyltransferase in combination with TKI.
    Blood. 2017;129:1008-1020.
    PubMed     Text format     Abstract available


  237. YOSHIZATO T, Nannya Y, Atsuta Y, Shiozawa Y, et al
    Impact of genetic alterations in stem-cell transplantation for myelodysplasia and secondary acute myeloid leukemia.
    Blood. 2017 Feb 21. pii: blood-2016-12-754796. doi: 10.1182/blood-2016-12-754796
    PubMed     Text format     Abstract available


  238. NAKATA Y, Ueda T, Nagamachi A, Yamasaki N, et al
    Acquired expression of CblQ367P in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia.
    Blood. 2017 Feb 16. pii: blood-2016-06-724658. doi: 10.1182/blood-2016-06-724658
    PubMed     Text format     Abstract available


  239. KORN C, Mendez-Ferrer S
    Myeloid malignancies and the microenvironment.
    Blood. 2017;129:811-822.
    PubMed     Text format     Abstract available


  240. LANEUVILLE P
    Stopping second-generation TKIs in CML.
    Blood. 2017;129:805-806.
    PubMed     Text format    


  241. POURABDOLLAH M, Chang H
    Myelodysplastic syndrome with excess blasts-2 associated with erythroid predominance.
    Blood. 2017;129:918.
    PubMed     Text format    


  242. REITER A, Gotlib J
    Myeloid neoplasms with eosinophilia.
    Blood. 2017;129:704-714.
    PubMed     Text format     Abstract available


  243. MYKLEBUST JH, Brody J, Kohrt HE, Kolstad A, et al
    Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
    Blood. 2017;129:759-770.
    PubMed     Text format     Abstract available


  244. ALSULIMAN A, Muftuoglu M, Khoder A, Ahn YO, et al
    A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML.
    Blood. 2017;129:740-758.
    PubMed     Text format     Abstract available


  245. MILNE TA
    Mouse models of MLL leukemia: recapitulating the human disease.
    Blood. 2017 Feb 8. pii: blood-2016-10-691428. doi: 10.1182/blood-2016-10-691428.
    PubMed     Text format     Abstract available


  246. CAMPANA D, Pui CH
    Minimal residual disease-guided therapy in childhood acute lymphoblastic leukemia.
    Blood. 2017 Feb 6. pii: blood-2016-12-725804. doi: 10.1182/blood-2016-12-725804.
    PubMed     Text format    


  247. THOMAS D, Majeti R
    Biology and relevance of human acute myeloid leukemia stem cells.
    Blood. 2017 Feb 3. pii: blood-2016-10-696054. doi: 10.1182/blood-2016-10-696054.
    PubMed     Text format     Abstract available


  248. HOLYOAKE TL, Vetrie D
    The chronic myeloid leukemia stem cell: stemming the tide of persistence.
    Blood. 2017 Feb 3. pii: blood-2016-09-696013. doi: 10.1182/blood-2016-09-696013.
    PubMed     Text format     Abstract available


  249. POLLYEA DA, Jordan CT
    Therapeutic targeting of acute myeloid leukemia stem cells.
    Blood. 2017 Feb 3. pii: blood-2016-10-696039. doi: 10.1182/blood-2016-10-696039.
    PubMed     Text format     Abstract available


  250. LOWENBERG B
    Introduction to the Review Series on Leukemic Stem Cells.
    Blood. 2017 Feb 3. pii: blood-2017-01-753319. doi: 10.1182/blood-2017-01-753319.
    PubMed     Text format    


  251. GODWIN CD, McDonald GB, Walter RB
    Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia.
    Blood. 2017 Feb 2. pii: blood-2017-01-762419. doi: 10.1182/blood-2017-01-762419.
    PubMed     Text format    


  252. COMOLI P, Basso S, Riva G, Barozzi P, et al
    BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors.
    Blood. 2017;129:582-586.
    PubMed     Text format     Abstract available


  253. PRATZ KW, Levis M
    How I treat FLT3-mutated AML.
    Blood. 2017;129:565-571.
    PubMed     Text format     Abstract available


  254. LULLA P, Heslop HE
    Fall of the mutants: T cells targeting BCR-ABL.
    Blood. 2017;129:539-540.
    PubMed     Text format    


    January 2017
  255. ISHIZAWA J, Sugihara E, Kuninaka S, Mogushi K, et al
    FZR1 loss increases sensitivity to DNA damage and consequently promotes murine and human B cell acute leukemia.
    Blood. 2017 Jan 31. pii: blood-2016-07-726216. doi: 10.1182/blood-2016-07-726216
    PubMed     Text format     Abstract available


  256. LAOUEDJ M, Tardif MR, Gil L, Raquil MA, et al
    S100A9 induces differentiation of acute myeloid leukemia cells through TLR4.
    Blood. 2017 Jan 30. pii: blood-2016-09-738005. doi: 10.1182/blood-2016-09-738005
    PubMed     Text format     Abstract available


  257. XU J, Li S
    Blasts with abundant cytoplasmic granules: acute myeloid leukemia or granular acute lymphoblastic leukemia?
    Blood. 2017;129:537.
    PubMed     Text format    


  258. GHIA P, Scarfo L, Perez S, Pathiraja K, et al
    Efficacy and safety of dinaciclib versus ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia.
    Blood. 2017 Jan 26. pii: blood-2016-10-748210. doi: 10.1182/blood-2016-10-748210
    PubMed     Text format    


  259. PYZER AR, Stroopinsky D, Rajabi H, Washington A, et al
    MUC1 mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.
    Blood. 2017 Jan 26. pii: blood-2016-07-730614. doi: 10.1182/blood-2016-07-730614
    PubMed     Text format     Abstract available


  260. DOHNER H, Estey E, Grimwade D, Amadori S, et al
    Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.
    Blood. 2017;129:424-447.
    PubMed     Text format     Abstract available


  261. CHESNAIS V, Arcangeli ML, Delette C, Rousseau A, et al
    Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Blood. 2017;129:484-496.
    PubMed     Text format     Abstract available


  262. WARFVINGE R, Geironson Ulfsson L, Sommarin MN, Lang S, et al
    Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.
    Blood. 2017 Jan 25. pii: blood-2016-07-728873. doi: 10.1182/blood-2016-07-728873
    PubMed     Text format     Abstract available


  263. BOCHTLER T, Granzow M, Stolzel F, Kunz C, et al
    Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia.
    Blood. 2017 Jan 24. pii: blood-2016-09-738161. doi: 10.1182/blood-2016-09-738161
    PubMed     Text format     Abstract available


  264. MARKS DI, Rowntree C
    A review of the management of adults with T-cell acute lymphoblastic leukemia.
    Blood. 2017 Jan 23. pii: blood-2016-07-692608. doi: 10.1182/blood-2016-07-692608
    PubMed     Text format     Abstract available


  265. SANCHEZ-MARTIN M, Ferrando A
    The NOTCH1-MYC highway towards T-cell acute lymphoblastic leukemia.
    Blood. 2017 Jan 23. pii: blood-2016-09-692582. doi: 10.1182/blood-2016-09-692582
    PubMed     Text format     Abstract available


  266. LAMY T, Moignet A, Loughran TP Jr
    LGL leukemia: from pathogenesis to treatment.
    Blood. 2017 Jan 23. pii: blood-2016-08-692590. doi: 10.1182/blood-2016-08-692590
    PubMed     Text format     Abstract available


  267. WATANABE T
    Adult T-cell leukemia (ATL): molecular basis for clonal expansion and transformation of HTLV-1-infected T cells.
    Blood. 2017 Jan 23. pii: blood-2016-09-692574. doi: 10.1182/blood-2016-09-692574
    PubMed     Text format     Abstract available


  268. FINCH ER, Tukaramrao DB, Goodfield LL, Quickel MD, et al
    Activation of PPARgamma by endogenous prostaglandin J2 mediates the antileukemic effect of selenium in murine leukemia.
    Blood. 2017 Jan 23. pii: blood-2016-08-736405. doi: 10.1182/blood-2016-08-736405
    PubMed     Text format     Abstract available


  269. LANOCHA AA, Zdziarska B
    T-cell lymphoblastic leukemia with t(11;22)(q24;q12) and EWSR1 rearrangement.
    Blood. 2017;129:393.
    PubMed     Text format    


  270. MUCHTAR E, Magen H, Gertz MA
    How I treat cryoglobulinemia.
    Blood. 2017;129:289-298.
    PubMed     Text format     Abstract available


  271. ALI ND, Weissmann D
    Charcot-Leyden crystals in T-cell lymphoblastic lymphoma.
    Blood. 2017;129:394.
    PubMed     Text format    


  272. VAINCHENKER W, Plo I
    P53 deletion and NrasG12D cooperate for AML.
    Blood. 2017;129:271-273.
    PubMed     Text format    


  273. DE WITTE T, Bowen D, Robin M, Malcovati L, et al
    Use of hematopoietic cell transplantation for patients with myelodysplastic syndrome and chronic myelomonocytic leukemia.
    Blood. 2017 Jan 17. pii: blood-2016-06-724500. doi: 10.1182/blood-2016-06-724500
    PubMed     Text format    


  274. WOYACH JA
    How I manage ibrutinib-refractory chronic lymphocytic leukemia.
    Blood. 2017 Jan 17. pii: blood-2016-09-693598. doi: 10.1182/blood-2016-09-693598
    PubMed     Text format     Abstract available


  275. MANTHA S, Goldman DA, Devlin SM, Lee JW, et al
    Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.
    Blood. 2017 Jan 12. pii: blood-2016-10-747170. doi: 10.1182/blood-2016-10-747170
    PubMed     Text format     Abstract available


  276. GANZEL C, Reinus C
    Nerves in bone marrow of newly diagnosed therapy-related acute myeloid leukemia.
    Blood. 2017;129:268.
    PubMed     Text format    


  277. XU Z, Beaulieu Bergeron M
    Near-triploid B lymphoblastic leukemia with Burkitt-like morphology.
    Blood. 2017;129:267.
    PubMed     Text format    


  278. ASKEW D, Pareek TK, Eid S, Ganguly S, et al
    Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice.
    Blood. 2017;129:246-256.
    PubMed     Text format     Abstract available


  279. ABU ZAID M, Wu J, Wu C, Logan BR, et al
    Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT.
    Blood. 2017;129:162-170.
    PubMed     Text format     Abstract available


  280. TARAFDAR A, Hopcroft LE, Gallipoli P, Pellicano F, et al
    CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
    Blood. 2017;129:199-208.
    PubMed     Text format     Abstract available


  281. NICOLINI FE
    CML stem cells: evasion for better invasion.
    Blood. 2017;129:141-142.
    PubMed     Text format    


  282. LEE LY, Hernandez D, Rajkhowa T, Smith SC, et al
    Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.
    Blood. 2017;129:257-260.
    PubMed     Text format    


  283. KHATER F, Lajoie M, Langlois S, Healy J, et al
    KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia.
    Blood. 2017 Jan 9. pii: blood-2016-10-744219. doi: 10.1182/blood-2016-10-744219.
    PubMed     Text format    


  284. GOOSSENS S, Peirs S, Van Loocke W, Wang J, et al
    Oncogenic ZEB2 activation drives sensitivity towards KDM1A inhibition in T-cell acute lymphoblastic leukemia.
    Blood. 2017 Jan 9. pii: blood-2016-06-721191. doi: 10.1182/blood-2016-06-721191.
    PubMed     Text format     Abstract available


  285. POURABDOLLAH M, Chang H
    Plasma cell neoplasm with plasmablastic morphology mimicking acute leukemia.
    Blood. 2017;129:132.
    PubMed     Text format    


  286. WALTER MJ
    Antecedent CHIP in CML?
    Blood. 2017;129:3-4.
    PubMed     Text format    


  287. LIU J, Guo B, Chen Z, Wang N, et al
    miR-125b promotes MLL-AF9-driven murine acute myeloid leukemia involving a VEGFA-mediated non-cell-intrinsic mechanism.
    Blood. 2017 Jan 4. pii: blood-2016-06-721027. doi: 10.1182/blood-2016-06-721027.
    PubMed     Text format     Abstract available


  288. CAO M, Li T, He Z, Wang L, et al
    Promyelocytic extracellular chromatin exacerbates coagulation and fibrinolysis in acute promyelocytic leukemia.
    Blood. 2017 Jan 4. pii: blood-2016-09-739334. doi: 10.1182/blood-2016-09-739334.
    PubMed     Text format     Abstract available


  289. AHN IE, Underbayev C, Albitar A, Herman SE, et al
    Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
    Blood. 2017 Jan 3. pii: blood-2016-06-719294. doi: 10.1182/blood-2016-06-719294.
    PubMed     Text format     Abstract available


    December 2016
  290. RAIMBAULT A, Chapuis N
    Plasma cell leukemia revealing a G6PD deficiency.
    Blood. 2016;128:3178.
    PubMed     Text format    



  291. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988;72(2):567-572.
    Blood. 2016;128:3017.
    PubMed     Text format    


  292. KIM E, Hurtz C, Koehrer S, Wang Z, et al
    Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.
    Blood. 2016 Dec 28. pii: blood-2016-06-722900. doi: 10.1182/blood-2016-06-722900
    PubMed     Text format     Abstract available


  293. MAXSON JE, Tyner JW
    Genomics of chronic neutrophilic leukemia.
    Blood. 2016 Dec 27. pii: blood-2016-10-695981. doi: 10.1182/blood-2016-10-695981
    PubMed     Text format     Abstract available



  294. Gallagher R, Collins S, Trujillo J, et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood. 1979;54(3):713-733.
    Blood. 2016;128:2871.
    PubMed     Text format    


  295. ABAZA Y, Kantarjian HM, Garcia-Manero G, Estey E, et al
    Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.
    Blood. 2016 Dec 21. pii: blood-2016-09-736686. doi: 10.1182/blood-2016-09-736686
    PubMed     Text format     Abstract available


  296. NISS ARFELT K, Barington L, Benned-Jensen T, Kubale V, et al
    EBI2 overexpression in mice leads to B1 B cell expansion and chronic lymphocytic leukemia-(CLL)-like B cell malignancies.
    Blood. 2016 Dec 21. pii: blood-2016-02-697185. doi: 10.1182/blood-2016-02-697185
    PubMed     Text format     Abstract available


  297. QU Y, Siggens L, Cordeddu L, Gaidzik VI, et al
    Cancer specific changes in DNA methylation reveal aberrant silencing and activation of enhancers in leukemia.
    Blood. 2016 Dec 21. pii: blood-2016-07-726877. doi: 10.1182/blood-2016-07-726877
    PubMed     Text format     Abstract available



  298. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood. 1977;50(3):481-492.
    Blood. 2016;128:2745.
    PubMed     Text format    


  299. FRANCIS SS, Wallace AD, Wendt GA, Li L, et al
    In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia.
    Blood. 2016 Dec 15. pii: blood-2016-07-723148.
    PubMed     Text format     Abstract available


  300. AUBERGER P, Puissant A
    Autophagy, a key mechanism of oncogenesis and resistance in leukemia.
    Blood. 2016 Dec 12. pii: blood-2016-07-692707.
    PubMed     Text format     Abstract available


  301. POWELL JA, Lewis AC, Zhu W, Toubia J, et al
    Targeting sphingosine kinase 1 induces MCL1 dependent cell death in acute myeloid leukemia.
    Blood. 2016 Dec 12. pii: blood-2016-06-720433.
    PubMed     Text format     Abstract available


  302. REA D, Nicolini FE, Tulliez M, Guilhot F, et al
    Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
    Blood. 2016 Dec 8. pii: blood-2016-09-742205.
    PubMed     Text format     Abstract available


  303. STRAMUCCI L, Perrotti D
    Twisting IL-1 signaling to kill CML stem cells.
    Blood. 2016;128:2592-2593.
    PubMed     Text format    


  304. BUNTING MD, Varelias A, Souza-Fonseca-Guimaraes F, Schuster IS, et al
    GVHD prevents NK-cell-dependent leukemia and virus-specific innate immunity.
    Blood. 2016 Dec 7. pii: blood-2016-08-734020.
    PubMed     Text format     Abstract available


  305. JAIN N, Roberts KG, Jabbour E, Patel K, et al
    Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.
    Blood. 2016 Dec 5. pii: blood-2016-07-726588.
    PubMed     Text format     Abstract available


  306. LEONG SR, Sukumaran S, Hristopoulos M, Totpal K, et al
    An anti-CD3 / anti-CLL-1 Bispecific Antibody for the treatment of Acute Myeloid Leukemia.
    Blood. 2016 Dec 1. pii: blood-2016-08-735365.
    PubMed     Text format     Abstract available


    November 2016
  307. SAFAVI S, Paulsson K
    Near-haploid and low hypodiploid acute lymphoblastic leukemia - two distinct subtypes but consistently poor prognosis.
    Blood. 2016 Nov 30. pii: blood-2016-10-743765.
    PubMed     Text format     Abstract available


  308. GREVER MR, Abdel-Wahab O, Andritsos LA, Banerji V, et al
    Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
    Blood. 2016 Nov 30. pii: blood-2016-01-689422.
    PubMed     Text format     Abstract available


  309. THEUNISSEN P, Mejstrikova E, Sedek L, van der Sluijs-Gelling AJ, et al
    Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia.
    Blood. 2016 Nov 30. pii: blood-2016-07-726307.
    PubMed     Text format     Abstract available


  310. GOTLIB J
    How I treat atypical chronic myeloid leukemia.
    Blood. 2016 Nov 29. pii: blood-2016-08-693630.
    PubMed     Text format     Abstract available



  311. Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123(15):2343-2354.
    Blood. 2016;128:2585.
    PubMed     Text format    


  312. DANESHBOD Y, Medeiros LJ
    Pseudo Chediak-Higashi anomaly in acute monoblastic leukemia.
    Blood. 2016;128:2583.
    PubMed     Text format    


  313. THAKRAL B, Khoury JD
    Histiocytic sarcoma: secondary neoplasm or "transdifferentiation" in the setting of B-acute lymphoblastic leukemia.
    Blood. 2016;128:2475.
    PubMed     Text format    



  314. Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511-533.
    Blood. 2016;128:2373.
    PubMed     Text format    


  315. WILLIAMS KM
    How I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
    Blood. 2016 Nov 16. pii: blood-2016-08-693507.
    PubMed     Text format     Abstract available


  316. CUSAN M, Vegi NM, Mulaw MA, Bamezai S, et al
    Controlled stem cell amplification by HOXB4 depends on its unique proline-rich region near the N-terminus.
    Blood. 2016 Nov 8. pii: blood-2016-04-706978.
    PubMed     Text format     Abstract available


  317. CUI B, Ghia EM, Chen L, Rassenti LZ, et al
    High-level ROR1 associates with accelerated disease-progression in chronic lymphocytic leukemia.
    Blood. 2016 Nov 4. pii: blood-2016-04-712562.
    PubMed     Text format     Abstract available


  318. ZHANG J, Kong G, Rajagopalan A, Lu L, et al
    p53-/- synergizes with enhanced NrasG12D signaling to transform megakaryocyte-erythroid progenitors in acute myeloid leukemia.
    Blood. 2016 Nov 4. pii: blood-2016-06-719237.
    PubMed     Text format     Abstract available


  319. GOLDBERG AD, Tallman MS
    Down for the count in acute myeloid leukemia.
    Blood. 2016;128:2195-2197.
    PubMed     Text format    


  320. NEFF JL, Chen D
    Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease.
    Blood. 2016;128:2275.
    PubMed     Text format    


  321. RYAN CE, Sahaf B, Logan AC, O'Brien S, et al
    Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
    Blood. 2016 Nov 1. pii: blood-2016-06-715284.
    PubMed     Text format     Abstract available


    October 2016

  322. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.
    Blood. 2016;128:2109.
    PubMed     Text format    


  323. BRAIG F, Brandt A, Goebeler M, Tony HP, et al
    Resistance to anti-CD19/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking.
    Blood. 2016 Oct 26. pii: blood-2016-05-718395.
    PubMed     Text format     Abstract available


  324. MITANI K, Nagata Y, Sasaki K, Yoshida K, et al
    Somatic mosaicism in chronic myeloid leukemia in remission.
    Blood. 2016 Oct 26. pii: blood-2016-06-723494.
    PubMed     Text format    


  325. TASIAN SK, Teachey DT, Li Y, Shen F, et al
    Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Blood. 2016 Oct 24. pii: blood-2016-05-707653.
    PubMed     Text format     Abstract available



  326. Lozzio CB, Lozzio BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood. 1975;45(3):321-334.
    Blood. 2016;128:1995.
    PubMed     Text format    


  327. LI H, Mar BG, Zhang H, Puram RV, et al
    The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia.
    Blood. 2016 Oct 18. pii: blood-2016-05-714493.
    PubMed     Text format     Abstract available


  328. BOTTONI A, Rizzotto L, Lai TH, Liu C, et al
    Targeting BTK through microRNA in chronic lymphocytic leukemia.
    Blood. 2016 Oct 17. pii: blood-2016-07-727750.
    PubMed     Text format     Abstract available


  329. KIM T, Tyndel MS, Kim HJ, Ahn JS, et al
    Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy.
    Blood. 2016 Oct 12. pii: blood-2016-04-708560.
    PubMed     Text format     Abstract available


  330. ANTONELLI A, Noort WA, Jaques J, de Boer B, et al
    Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.
    Blood. 2016 Oct 12. pii: blood-2016-05-719021.
    PubMed     Text format     Abstract available


  331. BALL M, List AF, Padron E
    When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia.
    Blood. 2016 Oct 5. pii: blood-2016-07-692988.
    PubMed     Text format     Abstract available


  332. MANCUSI A, Ruggeri L, Velardi A
    Haploidentical hematopoietic transplantation for the cure of leukemia: from its biology to clinical translation.
    Blood. 2016 Oct 3. pii: blood-2016-07-730564.
    PubMed     Text format     Abstract available


  333. ANDERSSON E, Tanahashi T, Sekiguchi N, Gasparini VR, et al
    High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia.
    Blood. 2016 Oct 3. pii: blood-2016-06-724856.
    PubMed     Text format    


    September 2016
  334. DAGKLIS A, Demeyer S, De Bie J, Radaelli E, et al
    Hedgehog pathway activation in T-cell acute lymphoblastic leukemia predicts response to SMO and GLI1 inhibitors.
    Blood. 2016 Sep 30. pii: blood-2016-03-703454.
    PubMed     Text format     Abstract available



  335. Wang L, Man N, Sun X-J, et al. Regulation of AKT signaling by Id1 controls t(8;21) leukemia initiation and progression. Blood. 2015;126(5):640-650.
    Blood. 2016;128:1778.
    PubMed     Text format    


  336. CHIANG MY, Wang Q, Gormley AC, Stein SJ, et al
    High selective pressure for Notch1 mutations that induce Myc in T cell acute lymphoblastic leukemia.
    Blood. 2016 Sep 26. pii: blood-2016-01-692855.
    PubMed     Text format     Abstract available


  337. KAJAL B, Chang H
    Acute myeloid leukemia with myelodysplasia-related changes demonstrating mixed-lineage phenotype.
    Blood. 2016;128:1663.
    PubMed     Text format    


  338. HU Z, Sun T
    Blastic plasmacytoid dendritic cell neoplasm associated with chronic myelomonocytic leukemia.
    Blood. 2016;128:1664.
    PubMed     Text format    


  339. KOTROVA M, Musilova A, Stuchly J, Fiser K, et al
    Distinct bilineal leukemia immunophenotypes are not genetically determined.
    Blood. 2016 Sep 13. pii: blood-2016-07-725861.
    PubMed     Text format    


  340. ZEBISCH A, Lal R, Muller M, Lind K, et al
    Acute myeloid leukemia with TP53 germline mutations.
    Blood. 2016 Sep 12. pii: blood-2016-08-732610.
    PubMed     Text format    


  341. DA CUNHA-BANG C, Christiansen I, Niemann CU
    The International prognostic Index for patients with chronic lymphocytic leukemia (CLL-IPI) applied in a population-based cohort.
    Blood. 2016 Sep 7. pii: blood-2016-07-724740.
    PubMed     Text format    


    August 2016
  342. DRUHAN LJ, McMahon DP, Steuerwald N, Price AE, et al
    Chronic neutrophilic leukemia in a child with a CSF3R T618I germline mutation.
    Blood. 2016 Aug 31. pii: blood-2016-07-730606.
    PubMed     Text format    


  343. FALINI B, Martelli MP, Tiacci E
    BRAF-V600E mutation in hairy cell leukemia: from bench to bedside.
    Blood. 2016 Aug 23. pii: blood-2016-07-418434.
    PubMed     Text format     Abstract available



  344. Ellison RR, Holland JF, Weil M, et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood. 1968;32(4):507-523.
    Blood. 2016;128:883.
    PubMed     Text format    


  345. FERREIRA TZ, Sandes AF
    Lymphocytosis, villi, and nucleoli: a variant of hairy cell leukemia.
    Blood. 2016;128:1018.
    PubMed     Text format    


  346. SPEEDY HE, Kinnersley B, Chubb D, Broderick P, et al
    Germline mutations in shelterin complex genes are associated with familial chronic lymphocytic leukemia.
    Blood. 2016 Aug 15. pii: blood-2016-01-695692.
    PubMed     Text format     Abstract available


  347. COOMBS J, Bera E
    B cells mimicking blasts after an allogeneic stem cell transplantation.
    Blood. 2016;128:881.
    PubMed     Text format    


  348. SUMITOMO Y, Koya J, Nakazaki K, Kataoka K, et al
    Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia.
    Blood. 2016 Aug 1. pii: blood-2015-12-684696.
    PubMed     Text format     Abstract available


    July 2016

  349. Dameshek W. Chronic lymphocytic leukemia-an accumulative disease of immunologically incompetent lymphocytes. Blood. 1967;29(4):566-584.
    Blood. 2016;128:465.
    PubMed     Text format    


  350. CAI Q, Jeannet R, Hua WK, Cook GJ, et al
    CBFbeta-SMMHC creates aberrant megakaryocyte-erythroid progenitors prone to leukemia-initiation in mice.
    Blood. 2016 Jul 21. pii: blood-2016-01-693119.
    PubMed     Text format     Abstract available


  351. HO TC, LaMere M, Stevens BM, Ashton JM, et al
    Evolution of acute myelogenous leukemia stem cell properties following treatment and progression.
    Blood. 2016 Jul 15. pii: blood-2016-02-695312.
    PubMed     Text format     Abstract available


  352. MIYOSHI H, Kiyasu J, Kato T, Yoshida N, et al
    PD-L1 expression on neoplastic or stromal cell is respectively poor or good prognostic factor for adult T-cell leukemia/lymphoma.
    Blood. 2016 Jul 14. pii: blood-2016-02-698936.
    PubMed     Text format     Abstract available


  353. MONTEWIS A, Eveillard M
    Acute myeloid leukemia with erythrophagocytosis indicative of KAT6A rearrangement.
    Blood. 2016;128:314.
    PubMed     Text format    


  354. ZHU H, Hu J, Chen L, Zhou W, et al
    The 12-year follow-up of survival, chronic adverse effects and retention of arsenic in patients with acute promyelocytic leukemia.
    Blood. 2016 Jul 11. pii: blood-2016-02-699439.
    PubMed     Text format    


  355. WOLLESCHAK D, Heidel FH
    Chronic myelogenous leukemia evolving after treatment of multiple myeloma.
    Blood. 2016;128:146.
    PubMed     Text format    


  356. ELENA C, Galli A, Such E, Meggendorfer M, et al
    Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia.
    Blood. 2016 Jul 6. pii: blood-2016-05-714030.
    PubMed     Text format     Abstract available


    June 2016

  357. Whang J, Frei E III, Tjio JH, Carbone PP, Brecher G. The distribution of the Philadelphia chromosome in patients with chronic myelogenous leukemia. Blood. 1963;22(6):664-673.
    Blood. 2016;127:3295.
    PubMed     Text format    


  358. THOMPSON MP, Waters TM, Kaplan EK, McKillop CN, et al
    Hospital volume and acute myeloid leukemia mortality in Medicare beneficiaries aged 65 and older.
    Blood. 2016 Jun 29. pii: blood-2016-05-716662.
    PubMed     Text format    


  359. LIBOUREL EJ, Klerk CP, van Norden Y, de Maat MP, et al
    Disseminated intravascular coagulation at diagnosis is a strong predictor for both arterial and venous thrombosis in newly diagnosed acute myeloid leukemia.
    Blood. 2016 Jun 28. pii: blood-2016-02-701094.
    PubMed     Text format     Abstract available


  360. RASHIDI A, Walter RB, Tallman MS, Appelbaum FR, et al
    Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.
    Blood. 2016 Jun 27. pii: blood-2016-03-674127.
    PubMed     Text format    


  361. RAU RE, Rodriguez B, Luo M, Jeong M, et al
    DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
    Blood. 2016 Jun 22. pii: blood-2015-11-684225.
    PubMed     Text format     Abstract available


  362. LEIVA-JUAREZ MM, Ware HH, Kulkarni VV, Zweidler-McKay PA, et al
    Inducible epithelial resistance protects mice against leukemia-associated pneumonia.
    Blood. 2016 Jun 17. pii: blood-2016-03-708511.
    PubMed     Text format     Abstract available


  363. KOSCIUCZUK EM, Saleiro D, Kroczynska B, Beauchamp EM, et al
    Merestinib blocks MNK kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo.
    Blood. 2016 Jun 15. pii: blood-2016-02-698704.
    PubMed     Text format     Abstract available


  364. METZELER KH, Herold T, Rothenberg-Thurley M, Amler S, et al
    Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
    Blood. 2016 Jun 10. pii: blood-2016-01-693879.
    PubMed     Text format     Abstract available


  365. GREVER MR
    BRAF inhibitor: targeted therapy in hairy cell leukemia.
    Blood. 2016;127:2784-5.
    PubMed     Text format    


  366. PIYA S, Kornblau SM, Ruvolo VR, Mu H, et al
    Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia.
    Blood. 2016 Jun 7. pii: blood-2016-01-692244.
    PubMed     Text format     Abstract available


    May 2016
  367. LAMPSON BL, Kasar SN, Matos TR, Morgan EA, et al
    Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.
    Blood. 2016 May 31. pii: blood-2016-03-707133.
    PubMed     Text format     Abstract available


  368. SHORT NJ, Jabbour E, Sasaki K, Patel K, et al
    Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Blood. 2016 May 27. pii: blood-2016-03-707562.
    PubMed     Text format     Abstract available


  369. THIJSSEN R, Ter Burg J, Garrick B, van Bochove GG, et al
    Dual TORK/DNA-PK inhibition blocks critical signalling pathways in chronic lymphocytic leukemia.
    Blood. 2016 May 27. pii: blood-2016-02-700328.
    PubMed     Text format     Abstract available


  370. OFRAN Y, Tallman MS, Rowe JM
    How I treat acute myeloid leukemia presenting with preexisting comorbidities.
    Blood. 2016 May 27. pii: blood-2016-01-635060.
    PubMed     Text format     Abstract available


  371. THORNE SH
    Virus fuels NK cell killing of leukemia.
    Blood. 2016;127:2509.
    PubMed     Text format    


  372. GUO B, Zhang L, Chiorazzi N, Rothstein TL, et al
    IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.
    Blood. 2016 May 25. pii: blood-2015-11-682997.
    PubMed     Text format     Abstract available


  373. ELMAAGACLI AH, Koldehoff M
    Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia.
    Blood. 2016 May 23. pii: blood-2016-04-713644.
    PubMed     Text format    


  374. HANDGRETINGER R, Lang P, Andre MC
    Exploitation of Natural Killer (NK) cells for the treatment of acute leukemia.
    Blood. 2016 May 20. pii: blood-2015-12-629055.
    PubMed     Text format     Abstract available


  375. BAHMANYAR M, Chang H
    Acute myeloid leukemia with myelodysplasia-related changes demonstrating prominent basophilic differentiation.
    Blood. 2016;127:2503.
    PubMed     Text format    


  376. RASHIDI A, Fisher SI
    EBV-associated aggressive natural killer cell leukemia.
    Blood. 2016;127:2502.
    PubMed     Text format    


  377. MOORE EM, Roth CG
    Plasma cell leukemia mimicking acute myeloid leukemia.
    Blood. 2016;127:2359.
    PubMed     Text format    



  378. Heyssel R, Brill AB, Woodbury LA, et al. Leukemia in Hiroshima atomic bomb survivors. Blood. 1960;15(3):313-331.
    Blood. 2016;127:2165.
    PubMed     Text format    


    April 2016
  379. SMALLWOOD DT, Apollonio B, Willimott S, Lezina L, et al
    Extracellular vesicles released by CD40/IL-4 stimulated chronic lymphocytic leukemia cells confer altered functional properties to CD4+ T cells.
    Blood. 2016 Apr 26. pii: blood-2015-11-682377.
    PubMed     Text format     Abstract available


  380. MA HS, Greenblatt SM, Shirley CM, Duffield AS, et al
    All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
    Blood. 2016 Apr 21. pii: blood-2015-05-646786.
    PubMed     Text format     Abstract available


  381. WILLIAMS MT, Yousafzai YM, Elder A, Rehe K, et al
    The ability to cross the blood-cerebrospinal fluid barrier is a generic property of acute lymphoblastic leukemia blasts.
    Blood. 2016;127:1998-2006.
    PubMed     Text format     Abstract available


  382. MICHEL G, Galambrun C, Sirvent A, Pochon C, et al
    Single versus double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome.
    Blood. 2016 Apr 20. pii: blood-2016-01-694349.
    PubMed     Text format     Abstract available


  383. JOHNSON SM, Dempsey C, Chadwick A, Harrison S, et al
    Metabolic reprogramming of bone marrow stromal cells by leukemic extracellular vesicles in acute lymphoblastic leukemia.
    Blood. 2016 Apr 20. pii: blood-2015-12-688051.
    PubMed     Text format    


  384. PARKER WT, Yeung DT, Yeoman AL, Altamura HK, et al
    The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib.
    Blood. 2016;127:1870-80.
    PubMed     Text format     Abstract available


  385. ARBER DA, Orazi A, Hasserjian R, Thiele J, et al
    The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia.
    Blood. 2016 Apr 11. pii: blood-2016-03-643544.
    PubMed     Text format     Abstract available


  386. BAZARBACHI A
    Tax fingerprint in adult T-cell leukemia.
    Blood. 2016;127:1737-8.
    PubMed     Text format    


  387. PARIKH SA, Strati P, Tsang M, West CP, et al
    Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis.
    Blood. 2016;127:1752-60.
    PubMed     Text format     Abstract available


  388. GU S, Chan WW, Mohi G, Rosenbaum J, et al
    Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1.
    Blood. 2016;127:1803-13.
    PubMed     Text format     Abstract available


    March 2016

  389. Frei E III, Holland JF, Schneiderman MA, et al. A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood. 1958;13(12):1126-1148.
    Blood. 2016;127:1621.
    PubMed     Text format    


  390. REDELL MS
    A STAT3 decoy lures AML out of hiding.
    Blood. 2016;127:1628-9.
    PubMed     Text format     Abstract available



  391. Bouroncle BA, Wiseman BK, Doan CA. Leukemic reticuloendotheliosis. Blood. 1958;13(7):609-630.
    Blood. 2016;127:1519.
    PubMed     Text format     Abstract available


  392. LUSKIN MR, Lee JW, Fernandez HF, Abdel-Wahab O, et al
    Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.
    Blood. 2016;127:1551-8.
    PubMed     Text format     Abstract available


  393. SCHULZE I, Rohde C, Scheller-Wendorff M, Baumer N, et al
    Increased DNA methylation of Dnmt3b targets impairs leukemogenesis.
    Blood. 2016;127:1575-86.
    PubMed     Text format     Abstract available


  394. STANLEY RF, Steidl U
    Ectopic DNMT3B expression delays leukemogenesis.
    Blood. 2016;127:1525-6.
    PubMed     Text format     Abstract available


  395. BABA T, Tanabe Y, Yoshikawa S, Yamanishi Y, et al
    MIP-1alpha/CCL3-expressing basophil-lineage cells drive the leukemic hematopoiesis of chronic myeloid leukemia in mice.
    Blood. 2016 Mar 22. pii: blood-2015-10-673087.
    PubMed     Text format     Abstract available


  396. WANG W, Cortes JE, Tang G, Khoury JD, et al
    Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
    Blood. 2016 Mar 22. pii: blood-2016-01-690230.
    PubMed     Text format     Abstract available


  397. WANQUET A, Birsen R, Lemal R, Hunault M, et al
    Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.
    Blood. 2016 Mar 18. pii: blood-2016-02-697193.
    PubMed     Text format    


  398. KADIA TM
    Release the hounds: virotherapy with immunotherapy.
    Blood. 2016;127:1381-3.
    PubMed     Text format     Abstract available


  399. DUPLOYEZ N, Marceau-Renaut A, Boissel N, Petit A, et al
    Comprehensive mutational profiling of core binding factor acute myeloid leukemia.
    Blood. 2016 Mar 15. pii: blood-2015-12-688705.
    PubMed     Text format     Abstract available


  400. NEESON P
    Allogeneic CAR19 cells clear ALL.
    Blood. 2016;127:1224-5.
    PubMed     Text format     Abstract available



  401. Rosenthal MC, Pisciotta AV, Komninos ZD, Goldenberg H, Dameshek W. The auto-immune hemolytic anemia of malignant lymphocytic disease. Blood. 1955;10(3):197-227.
    Blood. 2016;127:1217.
    PubMed     Text format    


  402. JACOBY E, Yang Y, Qin H, Chien CD, et al
    Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD.
    Blood. 2016;127:1361-70.
    PubMed     Text format     Abstract available


  403. MAN N, Sun XJ, Tan Y, Garcia-Cao M, et al
    Differential role of Id1 in MLL-AF9-driven leukemia based on cell of origin.
    Blood. 2016 Mar 4. pii: blood-2015-11-677708.
    PubMed     Text format     Abstract available


  404. DIETRICH S, Pircher A, Endris V, Peyrade F, et al
    BRAF inhibition in hairy cell leukemia with low dose vemurafenib.
    Blood. 2016 Mar 3. pii: blood-2015-11-680074.
    PubMed     Text format     Abstract available


    February 2016
  405. OLOMBEL G, Guerin E, Guy J, Perrot JY, et al
    The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.
    Blood. 2016 Feb 29. pii: blood-2016-01-689976.
    PubMed     Text format    


  406. CHEN Z, Hu S
    MYC/BCL2 double-hit lymphoma/leukemia mimicking acute leukemia at initial presentation.
    Blood. 2016;127:1072.
    PubMed     Text format    


  407. TAWANA K, Fitzgibbon J
    Inherited DDX41 mutations: 11 genes and counting.
    Blood. 2016;127:960-1.
    PubMed     Text format    


  408. BLACHLY JS
    Ribosomal revelation.
    Blood. 2016;127:958-9.
    PubMed     Text format    


  409. LEWINSOHN M, Brown AL, Weinel LM, Phung C, et al
    Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies.
    Blood. 2016;127:1017-23.
    PubMed     Text format     Abstract available


  410. MARCUCCI G, Li L
    Not only TKI! Targeting FLT3-ITD by autophagy.
    Blood. 2016;127:796-7.
    PubMed     Text format    


  411. WONG TN, Miller CA, Klco JM, Petti A, et al
    Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML.
    Blood. 2016;127:893-7.
    PubMed     Text format     Abstract available


  412. LARRUE C, Saland E, Boutzen H, Vergez F, et al
    Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells.
    Blood. 2016;127:882-92.
    PubMed     Text format     Abstract available


  413. TEIRA P, Battiwalla M, Ramanathan M, Barrett AJ, et al
    Early cytomegalovirus reactivation remains associated with increased transplant related mortality in the current era: a CIBMTR analysis.
    Blood. 2016 Feb 16. pii: blood-2015-11-679639.
    PubMed     Text format     Abstract available


  414. DEININGER MW, Hodgson JG, Shah NP, Cortes JE, et al
    Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.
    Blood. 2016;127:703-12.
    PubMed     Text format     Abstract available


  415. SAGLIO G, Fava C
    BCR-ABL1 mutation not equal ponatinib resistance.
    Blood. 2016;127:666-7.
    PubMed     Text format    


  416. MARTINEZ-TRILLOS A, Navarro A, Aymerich M, Delgado J, et al
    Clinical impact of MYD88 mutations in chronic lymphocytic leukemia.
    Blood. 2016 Feb 4. pii: blood-2015-10-678490.
    PubMed     Text format    


  417. ISHIKAWA S
    Opposite RHOA functions within the ATLL category.
    Blood. 2016;127:524-5.
    PubMed     Text format     Abstract available


  418. NADEU F, Delgado J, Royo C, Baumann T, et al
    Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1 and ATM mutations in chronic lymphocytic leukemia.
    Blood. 2016 Feb 2. pii: blood-2015-07-659144.
    PubMed     Text format     Abstract available


  419. PABST C, Bergeron A, Lavallee VP, Yeh J, et al
    GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo.
    Blood. 2016 Feb 1. pii: blood-2015-11-683649.
    PubMed     Text format     Abstract available


    January 2016
  420. VALSECCHI R, Coltella N, Belloni D, Ponente M, et al
    HIF-1alpha regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.
    Blood. 2016 Jan 29. pii: blood-2015-07-657056.
    PubMed     Text format     Abstract available


  421. PAGGETTI J, Moussay E
    BCR engagement in CLL: when translation goes wrong.
    Blood. 2016;127:378-80.
    PubMed     Text format     Abstract available


  422. MAUS MV
    Innate immune signaling in CLL.
    Blood. 2016;127:376-8.
    PubMed     Text format     Abstract available


  423. WALTER HS, Rule SA, Dyer MJ, Karlin L, et al
    A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
    Blood. 2016;127:411-9.
    PubMed     Text format     Abstract available


  424. WAGNER M, Oelsner M, Moore A, Gotte F, et al
    Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia.
    Blood. 2016;127:436-48.
    PubMed     Text format     Abstract available


  425. BELLON M, Lu L, Nicot C
    Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.
    Blood. 2016 Jan 26. pii: blood-2015-11-685032.
    PubMed     Text format     Abstract available


  426. FRAIETTA JA, Beckwith KA, Patel PR, Ruella M, et al
    Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
    Blood. 2016 Jan 26. pii: blood-2015-11-679134.
    PubMed     Text format     Abstract available


  427. ZHANG Q, Hossain DM, Duttagupta P, Moreira D, et al
    Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
    Blood. 2016 Jan 21. pii: blood-2015-08-665604.
    PubMed     Text format     Abstract available



  428. Farber S. Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. Blood. 1949;4(2):160-167.
    Blood. 2016;127:271.
    PubMed     Text format    


  429. AWAN FT
    Cure for CLL?
    Blood. 2016;127:274.
    PubMed     Text format    


  430. THOMPSON PA, Wierda WG
    Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL.
    Blood. 2016;127:279-86.
    PubMed     Text format     Abstract available


  431. LIBURA M, Giebel S, Piatkowska-Jakubas B, Pawelczyk M, et al
    Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.
    Blood. 2016;127:360-2.
    PubMed     Text format    


  432. FUJIKAWA D, Nakagawa S, Hori M, Kurokawa N, et al
    Polycomb-dependent epigenetic landscape in adult T-cell leukemia.
    Blood. 2016 Jan 15. pii: blood-2015-08-662593.
    PubMed     Text format     Abstract available


  433. MINUCCI S
    DNA binding modes of leukemia oncoproteins.
    Blood. 2016;127:177-8.
    PubMed     Text format    


  434. ARNOUX I, Loosveld M
    Hepatosplenic T-cell lymphoma: an acute leukemia presentation.
    Blood. 2016;127:269.
    PubMed     Text format    


  435. WOYACH JA
    FCR holds up to the test of time: CLL8 follow-up.
    Blood. 2016;127:172-3.
    PubMed     Text format    


  436. LIU J, Zhu HH, Jiang H, Jiang Q, et al
    Varying responses of PML-RARA with different genetic mutations to arsenic trioxide.
    Blood. 2016;127:243-50.
    PubMed     Text format     Abstract available


  437. FISCHER K, Bahlo J, Fink AM, Goede V, et al
    Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
    Blood. 2016;127:208-15.
    PubMed     Text format     Abstract available


  438. MIRANTES C, Dosil MA, Hills D, Yang J, et al
    Deletion of Pten in CD45-expressing cells leads to development of T-cell lymphoblastic lymphoma, but not myeloid malignancies.
    Blood. 2016 Jan 14. pii: blood-2015-09-669036.
    PubMed     Text format     Abstract available


  439. JAIN N, Lamb AE, O'Brien S, Ravandi F, et al
    Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.
    Blood. 2016 Jan 8. pii: blood-2015-08-661702.
    PubMed     Text format     Abstract available


  440. BURGER JA
    Obinutuzumab: the more the merrier?
    Blood. 2016;127:6-8.
    PubMed     Text format     Abstract available


  441. STEIN EM, Tallman MS
    Emerging therapeutic drugs for AML.
    Blood. 2016;127:71-8.
    PubMed     Text format     Abstract available


  442. AL-HUSSAINI M, Rettig MP, Ritchey JK, Karpova D, et al
    Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform.
    Blood. 2016;127:122-31.
    PubMed     Text format     Abstract available


  443. JAIN P, Kantarjian H, Patel KP, Nogueras Gonzalez G, et al
    Impact of BCR-ABL transcript type on response and survival in patients with chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Blood. 2016 Jan 4. pii: blood-2015-10-674242.
    PubMed     Text format     Abstract available


    December 2015
  444. HELSMOORTEL HH, Bresolin S, Lammens T, Cave H, et al
    LIN28B overexpression defines a novel fetal-like subgroup of juvenile myelomonocytic leukemia.
    Blood. 2015 Dec 28. pii: blood-2015-09-667808.
    PubMed     Text format     Abstract available


  445. SHEN W, Patnaik MM, Ruiz A, Russell SJ, et al
    Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Blood. 2015 Dec 28. pii: blood-2015-06-652503.
    PubMed     Text format     Abstract available


  446. ISLAM P, Daniel C, Strelec L, Kaye AH, et al
    Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia.
    Blood. 2015 Dec 23. pii: blood-2015-12-686873.
    PubMed     Text format    


  447. LJUNGSTROM V, Cortese D, Young E, Pandzic T, et al
    Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
    Blood. 2015 Dec 16. pii: blood-2015-10-674572.
    PubMed     Text format     Abstract available


  448. WOUTERS BJ, Delwel R
    Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia.
    Blood. 2015 Dec 10. pii: blood-2015-07-604512.
    PubMed     Text format     Abstract available


  449. GRIMWADE D, Ivey A, Huntly BJ
    Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.
    Blood. 2015 Dec 10. pii: blood-2015-07-604496.
    PubMed     Text format     Abstract available


  450. LOWENBERG B, Rowe JM
    Introduction to the Review Series on Advances in Acute Myeloid Leukemia (AML).
    Blood. 2015 Dec 10. pii: blood-2015-10-662684.
    PubMed     Text format    


  451. DOMBRET H, Gardin C
    An update of current treatments for adult acute myeloid leukemia.
    Blood. 2015 Dec 10. pii: blood-2015-08-604520.
    PubMed     Text format     Abstract available


  452. CORNELISSEN JJ, Blaise D
    Hematopoietic stem cell transplantation for patients with AML in first CR.
    Blood. 2015 Dec 10. pii: blood-2015-07-604546.
    PubMed     Text format     Abstract available


  453. UTTARKAR S, Dasse E, Coulibaly A, Steinmann S, et al
    Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
    Blood. 2015 Dec 2. pii: blood-2015-09-668632.
    PubMed     Text format     Abstract available


    November 2015
  454. KUCINE N, Marubayashi S, Bhagwat N, Papalexi E, et al
    Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
    Blood. 2015;126:2479-83.
    PubMed     Text format     Abstract available


  455. KAROL SE, Mattano LA Jr, Yang W, Maloney KW, et al
    Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia.
    Blood. 2015 Nov 20. pii: blood-2015-10-673848.
    PubMed     Text format     Abstract available


  456. LIU H, Sun X
    Pleomorphic plasma cell leukemia.
    Blood. 2015;126:2436.
    PubMed     Text format    


  457. LARSON RA
    Is there a best TKI for chronic phase CML?
    Blood. 2015;126:2370-5.
    PubMed     Text format     Abstract available


  458. STEENSMA DP
    Cytopenias + mutations - dysplasia = what?
    Blood. 2015;126:2349-51.
    PubMed     Text format    


  459. MATTHEWS GM, Mehdipour P, Cluse LA, Falkenberg KJ, et al
    Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies.
    Blood. 2015;126:2392-403.
    PubMed     Text format     Abstract available


  460. CARGO CA, Rowbotham N, Evans PA, Barrans SL, et al
    Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression.
    Blood. 2015;126:2362-5.
    PubMed     Text format     Abstract available


  461. VERHAGEN HJ, Smit MA, Rutten A, Denkers F, et al
    Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all trans retinoic acid.
    Blood. 2015 Nov 18. pii: blood-2015-07-653840.
    PubMed     Text format     Abstract available


  462. OROZCO JJ, Kenoyer A, Balkin ER, Gooley TA, et al
    Anti-CD45 radioimmunotherapy without TBI before BMT facilitates persistent haploidentical donor engraftment in a murine model.
    Blood. 2015 Nov 17. pii: blood-2014-12-617019.
    PubMed     Text format     Abstract available


  463. NAGATA Y, Kontani K, Enami T, Kataoka K, et al
    Variegated RHOA mutations in adult T-cell leukemia/lymphoma.
    Blood. 2015 Nov 16. pii: blood-2015-06-644948.
    PubMed     Text format     Abstract available


  464. KWOK M, Davies N, Agathanggelou A, Smith E, et al
    ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53 or ATM defective chronic lymphocytic leukemia cells.
    Blood. 2015 Nov 12. pii: blood-2015-05-644872.
    PubMed     Text format     Abstract available


  465. ARANGO M
    Adult T-cell leukemia/lymphoma.
    Blood. 2015;126:2343.
    PubMed     Text format    


  466. BOSCH F, Abrisqueta P
    Ibrutinib in CLL: 2 sides of the same coin.
    Blood. 2015;126:2173-4.
    PubMed     Text format    


    October 2015
  467. ZENZ T, Huber W
    Mutational landscape and complexity in CLL.
    Blood. 2015;126:2078-9.
    PubMed     Text format    


  468. GUIEZE R, Robbe P, Clifford R, de Guibert S, et al
    Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
    Blood. 2015;126:2110-7.
    PubMed     Text format     Abstract available


  469. LANDGREN O
    No CLL transmission through blood transfusion.
    Blood. 2015;126:1978-9.
    PubMed     Text format     Abstract available


  470. LI Z, Chen P, Su R, Li Y, et al
    Overexpression and knockout of miR-126 both promote leukemogenesis.
    Blood. 2015;126:2005-15.
    PubMed     Text format     Abstract available


  471. SCHMID C, Labopin M, Socie G, Daguindau E, et al
    Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation.
    Blood. 2015;126:2062-9.
    PubMed     Text format     Abstract available


  472. DEBORD C, Eveillard M
    Leukemic phase of a large B-cell lymphoma arising in KSHV-associated multicentric Castleman disease.
    Blood. 2015;126:1966.
    PubMed     Text format    


  473. EVEILLARD M, Moreau P
    Atypical plasma cell leukemia mistaken for lymphocytosis on blood count.
    Blood. 2015;126:1965.
    PubMed     Text format    


  474. SAMUDIO I, Konopleva M
    Targeting leukemia's "fatty tooth".
    Blood. 2015;126:1874-5.
    PubMed     Text format     Abstract available


  475. DEARDEN C
    So FCR, so good.
    Blood. 2015;126:1872-4.
    PubMed     Text format     Abstract available


  476. GAYNON PS
    ALL and osteonecrosis.
    Blood. 2015;126:1734-5.
    PubMed     Text format     Abstract available


  477. HWANG IS, Shin S, Min YH, Lee ST, et al
    NOTCH2 missplicing can occur in relation to apoptosis.
    Blood. 2015;126:1731-2.
    PubMed     Text format    


  478. PLESA A, Sujobert P
    This is not an erythroblast.
    Blood. 2015;126:1729.
    PubMed     Text format    


    September 2015
  479. OSHIMA M, Iwama A
    Nuclear, not cytoplasmic, PKR maneuvers in AML.
    Blood. 2015;126:1523-4.
    PubMed     Text format     Abstract available


  480. SPERLAZZA J, Rahmani M, Beckta J, Aust M, et al
    Depletion of the chromatin remodeler CHD4 sensitizes AML blasts to genotoxic agents and reduces tumor formation.
    Blood. 2015;126:1462-72.
    PubMed     Text format     Abstract available


  481. ORTUNO FJ, Sola M
    Extreme dyserythropoiesis in the setting of acute erythroid leukemia.
    Blood. 2015;126:1391.
    PubMed     Text format    


  482. EMADI A
    Exploiting AML vulnerability: glutamine dependency.
    Blood. 2015;126:1269-70.
    PubMed     Text format    


  483. CALIGARIS-CAPPIO F
    Directing CLL-cell traffic.
    Blood. 2015;126:1267-8.
    PubMed     Text format    


  484. SERODY J
    GVHD and miR: good things in small packages.
    Blood. 2015;126:1265-7.
    PubMed     Text format    


  485. MUKHERJEE S
    "Blood feuds".
    Blood. 2015;126:1264-5.
    PubMed     Text format    


  486. OCHODNICKA-MACKOVICOVA K, Bahjat M, Bloedjes TA, Maas C, et al
    NF-kappaB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activity.
    Blood. 2015;126:1324-35.
    PubMed     Text format     Abstract available


    August 2015
  487. APOLLONIO B, Ramsay AG
    Exosomes and CAFs: partners in crime.
    Blood. 2015;126:1053-5.
    PubMed     Text format     Abstract available


  488. MAHIEUX R
    A vaccine against HTLV-1 HBZ makes sense.
    Blood. 2015;126:1052-3.
    PubMed     Text format     Abstract available


  489. SUGATA K, Yasunaga J, Mitobe Y, Miura M, et al
    Protective effect of cytotoxic T lymphocytes targeting HTLV-1 bZIP factor.
    Blood. 2015;126:1095-105.
    PubMed     Text format     Abstract available


    July 2015
  490. CHENG H, Hao S, Liu Y, Pang Y, et al
    Leukemic marrow infiltration reveals a novel role for Egr3 as a potent inhibitor of normal hematopoietic stem cell proliferation.
    Blood. 2015 Jul 17. pii: blood-2015-01-623645.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: